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Abstract 
 
Treatment for cancer often involves combination therapies used both in medical practice 
and clinical trials.  Korn and Simon listed three reasons for the utility of combinations: 1) 
biochemical synergism, 2) differential susceptibility of tumor cells to different agents, and 3) 
higher achievable dose intensity by exploiting non-overlapping toxicities to the host.  Even if the 
toxicity profile of each agent of a given combination is known, the toxicity profile of the agents 
used in combination must be established.  Thus, caution is required when designing and 
evaluating trials with combination therapies.  Traditional clinical design is based on the 
consideration of a single drug.  However, a trial of drugs in combination requires a dose-
selection procedure that is vastly different than that needed for a single-drug trial.   
When two drugs are combined in a phase I trial, an important trial objective is to 
determine the maximum tolerated dose (MTD).  The MTD is defined as the dose level below the 
dose at which two of six patients experience drug-related dose-limiting toxicity (DLT). In phase 
I trials that combine two agents, more than one MTD generally exists, although all are rarely 
determined.  For example, there may be an MTD that includes high doses of drug A with lower 
doses of drug B, another one for high doses of drug B with lower doses of drug A, and yet 
another for intermediate doses of both drugs administered together.  With classic phase I trial 
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designs, only one MTD is identified. Our new trial design allows identification of more than one 
MTD efficiently, within the context of a single protocol.   
The two drugs combined in our phase I trial are temsirolimus and bevacizumab.  
Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) 
pathway which is fundamental for tumor growth and metastasis.  One mechanism of tumor 
resistance to antiangiogenic therapy is upregulation of hypoxia inducible factor 1α (HIF-1α) 
which mediates responses to hypoxic conditions.
 
  Temsirolimus has resulted in reduced levels of 
HIF-1α making this an ideal combination therapy. 
  Dr. Donald Berry developed a trial design schema for evaluating low, intermediate and 
high dose levels of two drugs given in combination as illustrated in a recently published paper in 
Biometrics entitled “A Parallel Phase I/II Clinical Trial Design for Combination Therapies.”  His 
trial design utilized cytotoxic chemotherapy. We adapted this design schema by incorporating 
greater numbers of dose levels for each drug.  Additional dose levels are being examined because 
it has been the experience of phase I trials that targeted agents, when given in combination, are 
often effective at dosing levels lower than the FDA-approved dose of said drugs. A total of 
thirteen dose levels including representative high, intermediate and low dose levels of 
temsirolimus with representative high, intermediate, and low dose levels of bevacizumab will be 
evaluated.   
We hypothesize that our new trial design will facilitate identification of more than one 
MTD, if they exist, efficiently and within the context of a single protocol.  Doses gleaned from 
this approach could potentially allow for a more personalized approach in dose selection from 
among the MTDs obtained that can be based upon a patient’s specific co-morbid conditions or 
anticipated toxicities. 
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Anticancer Drug Development 
 
Anticancer drug development adheres to an orderly and patterned process.  Preclinical 
data are collected, including information on efficacy, toxicology data, and mechanism(s) of 
action.  If a new drug in the preclinical setting shows promise, meaning that there is a reasonable 
expectation of safety and benefit to the patient, the drug will move forward in testing in three 
separate phases.  Phase I testing is performed to establish a recommended dose and schedule for 
phase II testing.  The recommended dose is based on observed toxic effects and pharmacokinetic 
outcomes.  Phase II testing is conducted to determine whether the drug shows any evidence of 
activity in a specific tumor type or subtype within a given tumor type.  Finally, the goal of phase 
III testing is to elucidate whether the new drug, alone or in combination, produces a meaningful 
response, as determined by increased overall survival, increased time to tumor progression, 
increased progression-free survival and/or other quality of life parameters.  It is important to 
note, however, that these separate phases are not mutually exclusive in that phase I testing seeks 
preliminary evidence of antitumor activity, whereas phase II and III testing continually 
reassesses drug safety and tolerability. 
Anticancer drug development began in the 1960s with cytotoxic chemotherapy.  The 
impetus during this time period was to define the maximum tolerated dose (MTD) as when the 
toxic effects of the drug, mainly myelosuppression, proved the desired effects of the new drug on 
the tumor (2-4).  However, over the past several decades, we have seen the emergence of 
rationally designed agents that target molecular pathways via intracellular and/or extracellular 
targets thought to be relevant to malignant transformation or development of metastases, with the 
additional objective of sparing noncancerous cells.   In this era of targeted therapy, many 
questions arise regarding the relevance of the “old” method of establishing the recommended 
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dose and schedule as the newer agents frequently do not produce traditional toxic effects, might 
not be directly cytotoxic, and ideally, produced effects only on defined subtypes within a specific 
tumor type.  Elizabeth Eisenhauer in “Phase I Cancer Clinical Trials:  A Practical Guide” asks 
the vital questions:  1)  Is dosing to toxicity appropriate or necessary? and, 2)  Can direct 
measures of target effect be utilized to determine dose(4)?  Regardless of the many questions that 
have arisen as to how best to proceed with phase I testing of newly developed targeted 
therapeutic agents, the fact remains that phase I trials are the gateway to drug development and 
approval.   
 
Phase I Trial Design 
Phase I trials generally have a small sample size and are nonrandomized, dose escalation 
studies.  For most trials, the endpoint is dose-limiting toxicity (DLT).   The range of doses to be 
evaluated is generally established on the basis of preclinical data.  The human starting dose of 
the drug in phase I testing is usually one-tenth of the lethal dose in 10% of animals [LD10].  The 
mouse toxic dose equivalent is typically used.  However, if other animal species show more 
toxicity, one-third to one-sixth of the lowest toxic dose equivalent is used from the most sensitive 
species.  
The MTD is usually defined as the dose at which one-third of patients experience a DLT.  
The recommended phase II dose is usually defined as the dose level just below the dose at which 
DLTs were observed in at least one-third of patients.  However, the MTD may be determined 
using the additional variables of drug cost, drug availability, and-or drug delivery issues. 
Dose escalation typically proceeds using a modified Fibonacci series, whereby the 
relative increase between successive dose levels is constant, e.g., 2.00, 1.67, 1.50, 1.40, 1.33, 
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1.33, etc.  The classical phase I trial design is a “3 + 3” design whereby three patients are 
enrolled on the first dose level.  If zero of three patients experience a DLT, three patients are then 
enrolled on the next dose level.  If two of three patients experience DLT, dose escalation will 
stop.  Three additional patients will then be enrolled on the next lowest dose level if only three 
patients were treated previously at that dose.  If one of three patients experiences a DLT, three 
more patients are enrolled.  Of those three additional patients, if none experience DLT, dose 
escalation will proceed; if one or more of this group suffers DLT, dose escalation will stop and 
the next lowest dose level is declared the MTD; and if two or more of this group experience 
DLT, dose escalation is stopped and three additional patients are enrolled on the next lowest dose 
level if only three patients were treated previously at that dose.   
 
Combination Therapy in Cancer Treatment 
Treatment for cancer often involves combination therapies used both in medical practice and 
clinical trials.  Korn and Simon listed three reasons for the utility of combinations: 1) 
biochemical synergism, 2) differential susceptibility of tumor cells to different agents, and 3) 
higher achievable dose intensity by exploiting non-overlapping toxicities to the host(5).  Even if 
the toxicity profile of each agent of a given combination is known, the toxicity profile of the 
agents used in combination must be established.  Thus, caution is required when designing and 
evaluating trials with combination therapies.  Traditional clinical design is based on the 
consideration of a single drug.  However, a trial of drugs in combination requires a dose-
selection procedure that is vastly different than that needed for a single-drug trial.   
When two drugs are combined in a phase I trial, an important trial objective is to determine 
the MTD and DLTs of the combination. In phase I trials that combine two agents, more than one 
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MTD generally exists, although all are rarely determined.  For example, there may be an MTD 
that includes high doses of drug A with lower doses of drug B, another one for high doses of 
drug B with lower doses of drug A, and yet another for intermediate doses of both drugs 
administered together.  With classic phase I trial designs, only one MTD is identified.  
        
Angiogenesis and Bevacizumab 
      Growing tumors receive nutrients, growth factors, oxygen, proteolytic enzymes, hemolytic 
factors, and hormones through the process of angiogenesis, which plays a key role in metastatic 
pathogenesis (6-8).  The vascular endothelial growth factor (VEGF) family of proteins and 
receptors are important in tumor angiogenesis and are fundamental for tumor growth and 
metastasis (9, 10).
 
  Bevacizumab is a monoclonal antibody specific for VEGF.    Bevacizumab 
binds to human VEGF and prevents interaction of VEGF with its receptors, FMS-like tyrosine 
kinase 1 (Flt-1) and kinase insert domain receptor (KDR) on the surface of endothelial cells (11).  
Bevacizumab works by inhibiting angiogenesis and thus may reduce microvascular growth of 
tumors and inhibit metastatic disease progression (11-13).   
Bevacizumab is administered intravenously (IV).   Bevacizumab is United States Food 
and Drug Administration (FDA) approved for use in combination IV fluorouracil-based 
chemotherapy as the first-line or second-line treatment for metastatic colon or rectal cancer at 5 
mg/kg or 10 mg/kg every 14 days.  Bevacizumab also has FDA approval in combination with 
carboplatin and paclitaxel for the first-line treatment of unresectable, locally advanced, recurrent 
or metastatic, non-squamous, non-small cell lung cancer (NSCLC) at 15 mg/kg every 21 days 
and in combination with paclitaxel chemotherapy for the first-line treatment of advanced human 
epidermal growth factor receptor-2 (HER-2) negative breast cancer at 10 mg/kg every two 
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weeks.  Finally, bevacizumab has FDA approval in metastatic renal cell carcinoma at 10 mg/kg 
every 14 days in combination with interferon alpha and in glioblastoma multiforme for patients 
who have progressed on prior therapy as a single agent at 10 mg/kg every 14 days.   
 
Resistance to Antiangiogeneic Therapy 
     Because diverse receptors in signaling networks communicate with each other via cross-talk, 
tumor growth and survival are regulated by various receptors and signaling pathways, not merely 
by one receptor or a single signaling pathway (14, 15).   Tumors often become resistant to 
antiangiogenic therapy.   One mechanism for such resistance is upregulation of HIF-1 α.  When 
HIF-1α is upregulated, adaptive responses to hypoxic conditions are modulated through its over-
expression, increasing levels of VEGF and subsequent aggressive tumor growth and infelicitous 
patient outcomes (8, 12, 16-26).
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Figure 1:  HIF-1α Pathway. 
Used with permission from Dr. Daniel Peet, Senior Lecturer. 
School of Molecular and Biomedical Science, University of Adelaide, Australia. 
CRICOS Provider Number 00123M 
http://www.adelaide.edu.au/mbs/research/peet/ 
 
 
 
Temsirolimus as an Inhibitor of HIF-1 
 
      Temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine/threonine 
kinase involved in the initiation of messenger ribonucleic acid (mRNA) translation (27, 28). In 
vitro studies with temsirolimus in renal cell carcinoma cell lines demonstrated inhibition of 
mTOR activity, and resulted in reduced levels of HIF-1α, HIF-2α  and VEGF (29).  Also, in the 
HER-2 gene amplified breast cancer cell line BT474, temsirolimus inhibited VEGF production 
in vitro under both normoxic and hypoxic conditions through inhibition of HIF-1 expression and 
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transcriptional activation (30).  Temsirolimus is administered IV and is FDA-approved as a first-
line therapy in patients with advanced renal cell carcinoma who had 3 or more of 6 poor 
prognostic factors at 25 mg IV given weekly (31).  
 
Rationale for Combining Bevacizumab and Temsirolimus 
      Temsirolimus inhibits HIF-1α, which abrogates its ability to render cancer cells resistant to 
antiangiogenic therapy.  Thus, temsirolimus is an excellent agent for combination with 
bevacizumab.  Furthermore, bevacizumab and temsirolimus as single agents have observed 
common toxicities that are non-overlapping.  Nonetheless, we plan to monitor patients very 
closely during the first cycle of combination therapy to evaluate safety and tolerability.  We also 
plan to establish the appropriate dose for phase II efficacy studies and provide preliminary data 
on antitumor activity.    
 
Novel Phase I Trial Design 
 
            Dr. Donald Berry developed a trial design schema allowing for evaluating low, 
intermediate and high dose levels of two drugs given in combination as illustrated in a recently 
published paper in Biometrics entitled “A Parallel Phase I/II Clinical Trial Design for 
Combination Therapies.(32)”   His trial design utilized cytotoxic chemotherapy. We adapted 
this design schema by incorporating greater numbers of dose levels for each drug.  Additional 
dose levels are being examined because it has been the experience of phase I trials that targeted 
agents, when given in combination, are often effective at dosing levels lower than the FDA-
approved dose of said drugs. 
 A total of thirteen dose levels including representative high, intermediate and low dose 
levels of temsirolimus with representative high, intermediate, and low dose levels of 
9 
 
bevacizumab will be evaluated.  This will allow us to identify multiple potential MTDs of each 
drug given in combination.  We are excited by this trial design as the classic phase I design 
would take three separate trials to determine this.       
We hypothesize that our new trial design will facilitate identification of more than one MTD, 
if they exist because the maximum dose of each drug is not tolerable in combination, efficiently 
and within the context of a single protocol.  Doses gleaned from this approach could potentially 
lead to a personalized approach in dose selection from among the MTDs obtained that can be 
based upon a patient‟s specific co-morbid conditions or anticipated toxicities. 
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PART II 
 
Clinical Trial Design: 
A Phase I Trial of Bevacizumab and Temsirolimus in 
Patients with Advanced Malignancies 
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Objectives 
 
Primary Objective 
  
 To determine the maximum tolerated doses (MTDs) and dose-limiting  
 
toxicities (DLTs) of combination treatment with bevacizumab and temsirolimus. 
 
 
Secondary Objectives 
 
 Preliminary descriptive assessment of antitumor efficacy. 
 
 Assessment of antiangiogenesis correlates. 
 
Timeline 
 
 The clinical trial of bevacizumab and temsirolimus in patients with advanced  
malignancies was approved by the M. D. Anderson Cancer Center Institutional Board Review 
(IRB) on October 25, 2007, and was activated at M. D. Anderson Cancer Center on January 25, 
2008.  The trial began patient accrual in February 2008.  
We estimate that the number of patients required to find the MTDs of this drug 
combination and to obtain adequate correlative studies is approximately 50-60 patients. The 
allowable number of patients that can be enrolled on the trial, given 13 total dose levels, is 78 
patients (if six patients are enrolled at each dose level).  Also, predicting that we may discover 3-
4 potential MTDs and allowing for expansion of 10 additional patients at those MTDs, we expect 
an absolute maximum of 118 patients for the trial.  However, it is important to note that we do 
not predict that all 13 dose levels will be explored due to some dosing levels being closed 
secondary to discovery of a DLT.  The estimated accrual rate is 1 - 5 patients per month.  All 
patients will be followed for 30 days after discontinuation of the study or after withdrawal from 
the study. 
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Rationale for Selected Dose and Schedule of Bevacizumab and Temsirolimus 
 
 We have designed this clinical trial combining bevacizumab and temsirolimus in  
patients with advanced malignancies on the basis of the following principles: 
1. Multiple dose levels of each drug are being examined because it has been the  phase I 
trial experience that targeted agents, when given in combination, are often effective at 
dosing levels lower than the FDA-approved dose of said drugs.  
2. The HIF-1α inhibition properties of temsirolimus make it an excellent agent for 
combination with bevacizumab in an effort to overcome resistance to antiangiogenic 
therapy.  
3. These two targeted agents have mostly non-overlapping toxicities and  might be 
amenable to escalation to full doses in combination.   
 
Bevacizumab is a recombinant, humanized, monoclonal antibody specific for VEGF(11).  
Bevacizumab binds to human VEGF and prevents interaction of VEGF with its receptors, Flt-1 
and KDR, on the surface of endothelial cells(11).  Bevacizumab is administered intravenously 
(IV).   Bevacizumab is United States Food and Drug Administration (FDA) approved for use in 
combination intravenous fluorouracil-based chemotherapy as a first-line or second-line treatment 
of metastatic colon or rectal cancer at 5 mg/kg or 10 mg/kg every 14 days.  Bevacizumab also 
has FDA approval in combination with carboplatin and paclitaxel for the first-line treatment of 
unresectable, locally advanced, recurrent or metastatic, non-squamous, non-small cell lung 
cancer (NSCLC) at 15 mg/kg every 21 days and in combination with paclitaxel chemotherapy 
for the first-line treatment of advanced human epidermal growth factor receptor-2 (HER-2) 
negative breast cancer at 10 mg/kg every two weeks.  Finally, bevacizumab has FDA approval in 
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metastatic renal cell carcinoma at 10 mg/kg every 14 days in combination with interferon alpha 
and in glioblastoma multiforme as a single agent for patients who have progressed on prior 
therapy as a single agent at 10 mg/kg every 14 days.  Based on these dosing schedules, we have 
decided to explore dosing levels ranging from 2.5 mg/kg to 15 mg/kg every 21 days.  
Temsirolimus [sirolimus 42-ester with 2,2-bis(hydroxymethyl) propionic-acid], an ester 
of the macrocyclic immunosuppressive agent sirolimus (rapamycin, Rapamune™), is a cytostatic 
cell cycle inhibitor with antitumor properties.  Temsirolimus inhibits mTOR, a serine/threonine 
kinase involved in the initiation of mRNA translation(27, 28).  Temsirolimus is administered IV.  
Temsirolimus is FDA-approved as a first-line therapy in patients with advanced renal cell 
carcinoma who had 3 or more of 6 poor prognostic factors at 25 mg IV given weekly(31).  On 
the basis of this dosing schedule, we have decided to explore dosing levels ranging from 5 mg to 
25 mg on days 1, 8, and 15 of a 21-day cycle. 
  At the above doses of bevacizumab and temsirolimus, observed common toxicities of 
each single agent are non-overlapping.  Nonetheless, we plan to monitor patients very closely 
with weekly labs and toxicity checks during the first cycle of combination therapy.     
 
Patient Selection 
 
“Inclusion Criteria 
1) Patients with advanced or metastatic cancer that is refractory to standard 
therapy, relapsed after standard therapy, or who have no standard therapy that 
induces a complete response (CR) rate of at least 10% or improves survival by at 
least three months. 
2) Patients should be at least four weeks from the last day of therapeutic radiation or 
cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-
cytotoxic targeted or biologic therapy. 
3) Eastern Cooperative Oncology Group (ECOG) performance status </= 2 
(Karnofsky >/= 60%).  See Appendix 1. 
4) Patients must have allowable organ and marrow function defined as: 
 absolute neutrophil count >/= 1,000/µL 
 platelets >/= 75,000/µL 
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 creatinine </= 3 X Institutional Upper Limit of 
Normal (IULN) 
 total bilirubin </= 3.0 mg/dL 
 AST(SGOT)/ALT(SGPT) </= 5 X IULN 
 fasting level of total cholesterol of no more than 350 mg/dL 
 triglyceride level of no more than 400 mg/dL 
5) Temsirolimus is a Pregnancy Category D drug. For this reason and because 
chemotherapeutic agents are known to be teratogenic, women of child-bearing 
potential (defined as women who are not post-menopausal for 12 months or who 
have had no previous surgical sterilization) and men must agree to use adequate 
contraception (hormonal or barrier method of birth control; abstinence) prior to 
study entry, for the duration of study participation, and for 90 days after the last 
dose. Should a women become pregnant or suspect she is pregnant while 
participating on this study, she should inform her treating physician immediately. 
6) Female patients of childbearing potential should have a normal plasma beta 
human chorionic gonadotropin (beta HCG). 
7) Ability to understand and the willingness to sign a written informed consent 
document. 
8) Patients may not be receiving any other investigational agents and/or any other 
concurrent anticancer agents or therapies. 
 
Exclusion Criteria 
1) Patients with hemoptysis within 28 days prior to entering the study. 
2) Patients with clinically significant unexplained bleeding within 28 days prior 
toentering the study. 
3) Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 
Mm Hg, diastolic blood pressure > 90 mm Hg on medication). 
4) Patients with clinically significant cardiovascular disease: 
 History of CVA within 6 months 
 Myocardial infarction or unstable angina within 6 months 
 Unstable angina pectoris 
5) Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection requiring parenteral antibiotics on Day 1. 
6) Pregnant or breastfeeding women.  Temsirolimus is Pregnancy Category D. 
7) History of hypersensitivity to bevacizumab, murine products, or any component of 
the formulation. 
8) History of hypersensitivity to temsirolimus or its metabolites (including 
sirolimus), polysorbate  80, or to any component of the formulation. 
9) Patients who are taking CYP3A4 inducers and/or inhibitors.  If a patient has a 
history of  taking CYP3A4 inducers and/or inhibitors prior to enrollment on protocol, 
a patient must wait at least 5 half-lives of said drug before initiating therapy on 
protocol. 
10) Patients with primary central nervous system (CNS) tumor or CNS metastases by 
head CT or MRI.”(33) 
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      Several changes were made to the above eligibility criteria after the information was posted 
on the website.  These changes are listed below: 
 Removed the exclusion criteria:   
6) Patients with primary central nervous system (CNS) tumor or CNS metastases  
by head CT or MRI. 
 Modified in the exclusion criteria: 
4) Patients must have allowable organ and marrow function defined as platelets >/= 
50,000/µL 
 Removed the exclusion criteria: 
5) Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection requiring parenteral antibiotics on Day 1.  
 Modified in the inclusion criteria: 
2) Patients may have received palliative radiation immediately before (or during) 
treatment provided radiation is not to the only target lesion available. 
 Modified in the inclusion criteria: 
If a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment 
on protocol, it is strongly recommended that the patient stops the drug and waits at 
least 5 half-lives of said drug before initiating therapy on protocol. 
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Treatment Plan 
 
Pretreatment Evaluation 
 
 As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, all patients will undergo rigorous 
evaluation and testing prior to the initiation of treatment, including the following: 
1) Complete history and physical examination, including documentation of all  
 
measurable disease as well as signs, symptoms, concurrent medications, and  
 
performance status.  
 
2) Laboratory studies: Complete blood count (CBC) with differential, sodium, potassium, 
chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, calcium, magnesium, 
albumin, alkaline phosphatase, total bilirubin, aspartate aminotransferase (SGOT[AST]), 
alanine aminotransferase (SGPT[ALT]), prothrombin time /partial thromboplastin time 
(PT/PTT), fasting serum total       cholesterol, fasting triglyceride level, urinalysis, serum 
pregnancy test (women of childbearing potential).  
      3)  12-lead electrocardiogram (EKG) within 28 days prior to starting treatment.  
      4)   Radiologic evaluation of measurable disease and pertinent tumor markers  
      within 4 weeks before starting treatment.  If the patient does not have  
      radiologically measurable disease but has cutaneously measurable disease, this  
      must be documented at the pretreatment evaluation physical examination (34).  
 
 
 
 
 
 
 
 
17 
 
Treatment 
 
 Treatment will be administered on an outpatient basis.  Both bevacizumab and  
temsirolimus infusions will be given at M. D. Anderson Cancer Center.  A cycle of therapy 
consists of 21 days.  No investigational or commercial agents or therapies other than those 
described here may be administered with the intent to treat the patient‟s malignancy. 
Temsirolimus 
 
 Temsirolimus will be given with bevacizumab on Day 1 of each cycle.   
 
Temsirolimus will be given as a single agent on Days 8 and 15 of each cycle.   
 
Temsirolimus infusions will be administered at the patient cohort dosing level  
 
IV over 60 minutes for the first cycle and over 30 minutes for subsequent  
 
cycles if the patient tolerates the first infusion well. 
 
 
Bevacizumab 
 
 Bevacizumab will be given on Day 1 only of each cycle.  Bevacizumab infusions  
 
will be administered at the patient cohort dosing level IV over 90 minutes for  
 
the first cycle and over 60 minutes for subsequent cycles if the patient tolerates the  
first infusion well. 
 
Trial Design 
 
We adapted Dr. Donald Berry's trial design schema (see Figure 2) as illustrated in  
 
a recently published paper in Biometrics entitled “A Parallel Phase I/II Clinical Trial  
 
Design for Combination Therapies” to allow for exploration of a greater number of dose  
 
levels. In doing this, we will be able to efficiently explore representative high,  
 
intermediate and low dose levels of temsirolimus with representative high, intermediate  
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and low dose levels of bevacizumab within the context of this one protocol.  Dose levels  
 
are found in Table 1. Figure 3 is a visual representation of our modified design schema.   
 
Whenever a dose level is determined to be above the MTD, all dose levels to the right of  
 
and above the vertical dotted line are no longer permissible as they would be expected to  
 
also be above the MTD.  For instance, if dose level 3 is above the MTD because of DLTs  
 
at that dose level, then dose levels 6, 9, and 13 would be expected to be above the MTD  
 
and would no longer be permissible (and would not be explored).    
 
 
 
 
 
Figure 2: An Illustration of Combination Doses. 
Used with permission from Dr. Donald Berry 
Division Head, Quantitative Sciences Division  
The University of Texas MD Anderson Cancer Center 
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TABLE 1: Dose-Escalation Schedule 
 
Dose Level  
                            Dose and Schedule (21-day cycle) 
Temsirolimus Bevacizumab 
Level 1  5 mg days 1, 8, and 15 every 21 days 5 mg/kg day 1 every 21 days  
Level 2  5 mg days 1, 8, and 15 every 21 days 10 mg/kg day 1 every 21 days  
Level 3  5 mg days 1, 8, and 15 every 21 days 15 mg/kg day 1 every 21 days 
Level 4  12.5 mg days 1, 8, and 15 every 21 days 2.5 mg/kg day 1 every 21 days 
Level 5  12.5 mg days 1, 8, and 15 every 21 days 7.5 mg/kg day 1 every 21 days 
Level 6  12.5 mg days 1, 8, and 15 every 21 days 15 mg/kg day 1 every 21 days 
Level 7  20 mg days 1, 8, and 15 every 21 days 2.5 mg/kg day 1 every 21 days 
Level 8  20mg days 1, 8, and 15 every 21 days 7.5 mg/kg day 1 every 21 days 
Level 9  20 mg days 1, 8, and 15 every 21 days 15 mg/kg day 1 every 21 days 
Level 10 25 mg days 1, 8, and 15 every 21 days 2.5 mg/kg day 1 every 21 days 
Level 11 25 mg days 1, 8, and 15 every 21 days 5 mg/kg day 1 every 21 days  
Level 12 25 mg days 1, 8, and 15 every 21 days 10 mg/kg day 1 every 21 days  
Level 13 25 mg days 1, 8, and 15 every 21 days 15 mg/kg day 1 every 21 days 
 
 
 
 
 
Figure 3: Treatment Plan:  Modified Design Schema 
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This protocol will utilize a Phase I escalation design (see Table 2) with three to four  
patients per cohort in an effort to obtain three evaluable patients. Three to four patients  
will be entered at each dose level in order to obtain adequate correlative data in  
addition to the safety data. Three to four patients will be treated at dose level 1 and  
evaluated for toxicity.  Dose escalation will then proceed as follows: 
 
Table 2:  Dose Escalation Design 
 
Number of Patients with DLT at a Given Dose Level Escalation Decision Rule 
0 out of 3 Enter 3 patients at the next dose level. 
>2 out of 3 Dose escalation will be stopped.  Three (3) additional 
patients will be entered at the next lowest dose level if only 
3 patients were treated previously at that dose. 
1 out of 3 
Enter at least 3 more patients at this dose level. 
 If 0 of these 3 patients experience DLT, proceed to the 
next dose level. 
 If 1 or more of this group suffer DLT, then dose 
escalation is stopped, and next lowest dose is declared as 
a maximum tolerated dose (MTD). 
 If 2 or more of this group suffer DLT, then dose 
escalation is stopped.  Three (3) additional patients will 
be entered at the next lowest dose level if only 3 patients 
were treated previously at that dose. 
 
 
Because of the specific design of this trial, more than one potential MTD may be  
identified.  As is standard for investigator initiated protocols in the Department 
Investigational Cancer Therapeutics at M.D. Anderson Cancer Center, the MTDs identified will 
be expanded by up to 10 additional patients to further evaluate toxicity and correlative data (34).  
       As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, up to three additional patients will be 
permitted to be added to a cohort for evaluation of safety and/or correlative studies.  These 
Modified from Cancer Therapy Evaluation Program (CTEP) website(1).  See Appendix 4. 
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patients will be considered in the DLT analysis.  If a response is observed in a particular tumor 
type with the study drug combination, enrollment will be permitted to be expanded to include a 
total of 14 patients with that tumor type.  All enrolled participants of that tumor type will be 
considered in the DLT analysis.  If at any time more than or equal to one-third of the participants 
at a dose level experience a DLT, that dose will be considered to be above the MTD, and the 
dose of the study drugs will be de-escalated.  A tumor response will be defined as one or more of 
the following:  1) stable disease for more than or equal to four months, 2) decrease in the sum of 
target lesions by more than or equal to 20% by RECIST criteria 1.0, or 3) decrease in tumor 
markers by more than or equal to 25% (34). 
As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, there will be no intra-patient dose 
escalation, and no patients will be enrolled at the next dose level until three patients enrolled at 
the previous dose level have completed at least three weeks of therapy.  If a DLT is observed in 
one of the three patients after one cycle, dose escalation will not proceed until six patients in the 
cohort have been assessed for toxicity after one cycle (34). 
As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, patients will continue treatment until 
their disease worsens, their side effects become too severe, or the patient‟s physician feels it is 
not in the patient‟s best interest to continue. A patient may also be discontinued for an 
intercurrent illness that prevents further administration of treatment.  A patient may also choose 
to discontinue enrollment in the protocol at any time(34).  Pre-medication, precautions, route, 
and schedule for each medication for each medication are described in Table 3. 
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TABLE 3: Regimen Description  
 
Agent  Premedications; 
Precautions  
Dose  Route  Schedule  Cycle 
Length  
Bevacizumab   ** in 
100cc 
of NS  
Initial dose is infused over 90 minutes. Infusion may be 
shortened to 60 minutes if the initial infusion is well 
tolerated. The third and subsequent infusions may be 
shortened to 30 minutes if the 60 minute infusion is well 
tolerated.  
Day 1 only 21 days  
Temsirolimus  CYP3A4 inhibitors 
CYP3A4 inducers 
 
Patients should 
receive prophylactic 
intravenous 
diphenhydramine 25-
50mg (or similar 
antihistamine) 
approximately 30 
minutes before the 
start of each dose of 
temsirolimus. 
** in 
250cc 
of NS 
The dose is infused over a 30-60 minute period once a 
week.   
Days 1,8, 
and 15 
21 days  
** Doses as appropriate for assigned dose level.  
*** Testing and drug administration will take place as per protocol unless patient/logistical/medical reasons intervene.  
 
 
Evaluation During Study 
 
As is standard for investigator initiated protocols in the Department 
Investigational Cancer Therapeutics at M.D. Anderson Cancer Center, all 
patients will undergo rigorous evaluation and testing during treatment, including the following: 
 Physical examination (including vital signs, weight, performance status) weekly during 
cycle 1.  Thereafter, patients will have a physical examination prior to starting the next 
cycle. 
 Labs to include CBC with differential, sodium, potassium, chloride, bicarbonate,  
BUN, creatinine, glucose, calcium, magnesium, albumin, alkaline phosphatase,  
total bilirubin, SGOT[AST], SGPT[ALT], fasting total cholesterol, fasting  
triglyceride level. These laboratory values will be obtained weekly during  
cycle 1.  Thereafter, patients will have labs drawn prior to starting the  
the next cycle.  
 Urinalysis during week 1 of each cycle.  
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 Radiologic evaluations and pertinent tumor markers will be repeated after every two 
cycles of treatment. The same radiologic method of assessment and the same 
technique should be used to characterize each identified and reported lesion at 
baseline and during follow-up as reflected in Table 4(34).  
 
Table 4:  Study Calendar  
  
Assessment Tool Baseline Cycle 1 Cycle 2 
Week Week 
1 2 3 1 2 3 
Temsirolimus*  X X X X X X 
Bevacizumab**  X   X   
History and Physical Exam X X X X X   
CBC with differential X X X X X   
Sodium, Potassium, Chloride, 
Bicarbonate, BUN, Creatinine, 
Glucose, Calcium, Magnesium 
X X X X X   
Albumin, Alkaline Phosphatase, 
Total Bilirubin, SGOT [AST], 
SGPT [ALT] 
X X X X X   
Urinalysis X X   X   
PT/PTT X       
Total Cholesterol, Triglyceride X X X X X   
Serum Pregnancy Test (in 
women with childbearing 
potential) 
X       
12-lead EKG X       
Appropriate Radiologic 
Evaluation 
X      X 
*   Temsirolimus:  Days 1, 8, and 15 every 21 days.  See Table 1 for dosing schedule 
**  Bevacizumab:  Day 1 every 21 days.  See Table 1 for dosing schedule 
 
 
Supportive Care:  Antiemetics and Growth Factors 
Initially, no antiemetics will be used prophylactically.  If an individual patient develops 
nausea and vomiting, therapeutic antiemetics will be used at the discretion of the patient‟s 
physician.  However, use of antiemetics must be recorded.  Prochlorperazine, metocloperamide, 
promethazine, or equivalent are suggested for grade 1-2 nausea and/or vomiting.  5-HT3 
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antagonists are suggested for grade 3-4 nausea and/or vomiting.  Dexamethasone is not 
recommended as it is a potent inducer of CYP3A4/5 and may decrease exposure to the active 
metabolite of temsirolimus, sirolimus.  Hematopoietic growth factors may be used following the 
National Comprehensive Cancer Network (NCCN) guidelines. 
Duration of Therapy 
 As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, in the absence of treatment delays due to 
adverse events, treatment may continue until one of the following criteria are met: 
 Progression of disease on combination therapy (bevacizumab and  
 
 temsirolimus).  Exception: If the patient is deriving clinical benefit from the  
 
treatment, then the patient may continue on study at the discretion of the 
 
principal investigator.  
 
 The development of unacceptable toxicity. 
 
 Physician recommendation for patient removal from study. 
 
 Patient elects to discontinue further treatment on the study medications. 
 
 Intercurrent illness that prevents further administration of treatment. 
 
For those patients achieving complete remission (CR) on combination therapy, they will 
continue combination therapy until disease progression (34). 
Criteria for Removal from the Study 
 As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, patients may be removed from protocol 
treatment for any of the following reasons: 
 Progressive disease (PD) on combination therapy (bevacizumab and  
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temsirolimus).  Patients who develop rapidly PD (as evidenced clinically, 
radiographically or via tumor markers) prior to the scheduled evaluation every two 
cycles or six weeks, may be taken off the study at the discretion of the principal 
investigator.  Exception: If the patient is deriving clinical benefit from the treatment, 
the patient may continue on study at the discretion of the principal investigator.  
 The development of unacceptable toxicity. 
 
 Physician recommendation for patient removal from study. 
 
 Patient elects to discontinue further treatment on the study medications. 
 
 Intercurrent illness that prevents further administration of treatment. 
 
 Delay in treatment for > 4 weeks due to treatment-related toxicity or patient non- 
 
compliance  (34). 
 
 
Evaluation of Toxicity and Guidelines for Dose Modification 
 Our primary objective is to determine the MTDs and DLTs of combination  
 
treatment with bevacizumab and temsirolimus in patients with advanced malignancies. 
 
Toxicities will be documented at each visit and described according to the National  
 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)  
 
Version 3.0.    
 
Safety Considerations 
As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, DLT is defined as the following: 
 Any grade 3 or 4 non-hematologic toxicity (as defined in the NCI CTCAE v3.0), even if 
expected and believed related to the study medications.  Exceptions:  nausea and 
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vomiting responsive to appropriate antiemetic regimens, diarrhea responsive to 
appropriate antidiarrheal regimens, correctable electrolyte abnormalities, or alopecia.  
 Any grade 4 hematologic toxicity lasting 2 weeks or longer (as defined by the NCI-
CTCAE v3.0), despite supportive care.  
 Any grade 4 nausea or vomiting > 5 days despite maximum anti-nausea regimens. 
 Any other grade 3 non-hematologic toxicity including symptoms/signs of vascular leak 
or cytokine release syndrome 
 Any severe or life-threatening complication or abnormality not defined in the NCI-
CTCAE that is attributable to the therapy.  
The MTD will be defined by DLTs that occur in the first cycle considered the induction phase 
and lasting three weeks in duration. The use of growth factors is accepted during the clinical 
study(34).  
Dose Modifications 
 
As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, if a patient experiences a toxicity at the 
first dose level, and if the toxicity is known to be related to one drug in the regimen, then a dose 
reduction of 50% of that drug is permitted after the patient recovers to </= grade 1 toxicity.  If, 
however, a patient experiences a toxicity at the first dose level and it is unclear which drug is the 
cause of the toxicity, then a dose reduction of 50% of all drugs in the regimen is permitted after 
the patient recovers to </= grade 1 toxicity(34). 
As is standard for investigator initiated protocols in the Department of Investigational 
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Cancer Therapeutics at M.D. Anderson Cancer Center, at subsequent dose levels, if a patient 
experiences a toxicity which is known to be related to one drug in the regimen, that drug may be 
de-escalated to the prior dose level after the patient recovers to </= grade 1 toxicity.  If, however, 
a patient experiences a toxicity for which it is unclear which drug is the cause of the toxicity, 
both drugs which were dose escalated to the current dose level may be de-escalated to the prior 
dose levels after the patient recovers to </= grade 1 toxicity(34).  
 
Criteria for Response and Progression 
While the primary objective of this study is to evaluate dose-ranging experience and the 
toxicity observed, a preliminary descriptive assessment of antitumor efficacy will be made.  
Evaluation of response will follow the Response Evaluation Criteria in Solid Tumors (RECIST) 
Guidelines 1.0 (35).  Response criteria are defined as follows in Tables 5 and 6. 
 
Table 5:  Evaluation of Target Lesions 
 
* Complete Response (CR): Disappearance of all target lesions 
* Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking 
as reference the baseline sum LD 
* Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the 
smallest sum LD (nadir) recorded since the treatment started or the appearance of one 
or more new lesions 
* Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, 
taking as reference the smallest sum LD since the treatment started 
 
        
 
 
 
 
 
Modified from CTEP website(1).  See Appendix 4. 
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Table 6:  Evaluation of Non-Target Lesions 
 
* Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level 
* Incomplete Response/          
Stable Disease (SD):  
Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker 
level above the normal limits 
* Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing 
non-target lesions (1)  
 
The best response to therapy is defined as the best response spanning the time from the 
start of the treatment until disease progression/recurrence.  The best response to therapy will be 
documented as complete response (CR), partial response (PR), progressive disease (PD), or 
stable disease (SD). 
 
                  Table 7: Evaluation of Best Overall Response 
Target lesions Non-Target lesions New Lesions Overall response 
CR CR No CR 
CR Non-CR/Non-PD/not 
evaluated 
No PR 
PR Non-CR/Non-PD/not 
evaluated 
No PR 
SD Non-CR/Non-PD/not 
evaluated 
No SD 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
 
 
 
Modified from CTEP website(1).  See Appendix 4. 
Modified from CTEP website (1).  See Appendix 4. 
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Statistical Considerations 
The primary objective of this study is to assess safety and tolerability as well as to define 
the MTDs of combination treatment with bevacizumab and temsirolimus in patients with 
advanced cancer.  An MTD is defined as the dose level below the dose at which two of six 
patients experience drug-related DLT in the first cycle.  Secondary objectives include a 
preliminary assessment of antitumor efficacy of each combination (objective response by 
RECIST criteria) and a preliminary assessment of correlation of surrogate antiangiogenesis 
markers with antitumor activity.  
As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, up to an additional 10 patients with 
biopsiable disease may be entered at the different MTD dose levels after they have been 
determined for the purpose of exploratory analysis with correlative studies(34).  Correlative 
studies include but are not limited to dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI), tumor biopsy, and peripheral blood markers.   
As is standard for investigator initiated protocols in the Department of Investigational 
Cancer Therapeutics at M.D. Anderson Cancer Center, during expansion, at any time > 33% of 
patients have a DLT, the expansion cohort will be terminated. If the dose expansion is terminated 
due to >33% of patients having a DLT, then an additional 10 patients may be entered at the next 
lowest dose level, for the purpose of exploratory analysis with correlative studies.   For these 
additional 10 patients, we will monitor toxicity using the same criteria used in the initial 
expansion cohorts (34). 
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Demographic and Clinical Characteristics 
      Fifty-six patients enrolled from February 2008 to October 2009.  The median age was 57 
years, with a range of 19-76 years.  At the time of enrollment, most patients had excellent 
performance status.  Eastern Cooperative Oncology Group (ECOG) performance status was 0 for 
13 (23%) of the patients, 1 for 36 (64%) of the patients, and 2 for seven (13%) of the patients.  
The patients had received extensive prior treatment including systemic therapy in 55 patients 
(98%), surgery in 48 patients (86%), and radiation in 33 patients (59%).  The median number of 
prior systemic therapies was 4, with a range of 0 to 11.  Sixteen patients (29%) had previously 
received treatment on a phase I trial.  The most common tumor types enrolled were 10 patients 
with colorectal cancer (19%), 6 patients with ovarian/peritoneal carcinoma (11%), and 5 patients 
with melanoma (9%).  One patient had primary central nervous system (CNS) tumor at the time 
of enrollment. 
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Toxicity Assessment 
        Dose level 13 (bevacizumab 15 mg/kg and temsirolimus 25 mg) was reached and no 
MTD was obtained as we were able to reach FDA-approved doses of both drugs.  Currently, two 
patients are actively receiving therapy.  Thirty-nine patients (70%) experienced no treatment-
related toxicity greater than grade 2. 
     Only one DLT was obtained in dose level 3 (bevacizumab 15 mg/kg and temsirolimus 
5mg).  The DLT was grade 3 hypertension.  Zero of three patients in the expansion cohort at 
dose level 3 experienced toxicity.  Grade 3 or 4 toxicities were observed in 17 patients (30%).  
Grade 4 toxicities included hypertriglyceridemia (1 patient) and thrombocytopenia (1 patient).  
Grade 3 toxicities included hypertension (1 patient), hypercholesterolemia (1 patient), 
hyperglycemia (1 patient), thrombocytopenia (2 patients), mucositis (1 patient), proteinuria (1 
patient), leukopenia (1 patient), neutropenia (1 patient) , elevated aspartate aminotransferase 
(AST) (2 patients), elevated alanine aminotransferase (ALT) (1 patient), fatigue (5 patients), and 
pneumonitis (1 patient).  Table 9 lists the NCI-CTCAE grade 3 and 4 treatment-related toxicities 
observed for all enrolled patients by dose level.  
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Table 9:  Treatment-Related Grade 3 and 4 Toxicities* 
(* Possibly, Probably, or Definitely treatment-related) 
Dose 
Level 
Number of 
Patients 
Patients with 
G3/G4 Toxicity 
DLTs Grade 3 and 4 Toxicities 
1 4 0 0 None 
2 4 0 0 None 
3 7 3 1 
G3 Hypertension (1); G4 
Triglycerides (1); G3 
Cholesterol (1) 
4 4 1 0 G3 Hyperglycemia (1) 
5 4 2 0 
G3 Mucositis (1); G3 
Proteinuria (1) 
6 4 2 0 
G3 Leukopenia (1); G3 
Neutropenia (1); G3 AST (1) 
7 4 0 0 None 
8 5 2 0 
G4 Thrombocytopenia (1); G3 
Fatigue (1) 
9 4 2 0 
G3 Fatigue (1); G3 
Thrombocytopenia (1) 
10 3 2 0 
G3 Fatigue (1); G3 ALT (1); G3 
AST (1) 
11 3 0 0 None 
12 4 1 0 G3 Fatigue (1);  
13 6 2 0 
G3 Fatigue (1); G3 
Thrombocytopenia (1); G3 
Pneumonitis (1) 
 
Three patients died while enrolled on the study.  The cause of death in each case was 
determined to be unrelated to the study medications.  The details of the cases are described 
below: 
1) Patient # 27, a 53-year old man with squamous cell carcinoma of the larynx with locally 
advanced disease involving the soft tissues of the neck and cervical lymph nodes was 
enrolled on dose level 6 (bevacizumab 15 mg/kg and temsirolimus 12.5 mg).  The patient 
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was treated in the hospital and on day 12 of the first cycle had a carotid artery blow-out 
that was fatal.   
 
 
 
Figure 4a: Images for Patient #27  
 
PATIENT #27
One day before start of chemo 11 Days after one dose of 
Bevacizumab (Day 1) & two doses 
of Temsirolimus (Day 1 & Day 8)
 
Figure 4b: Images for Patient #27      
One day before start of chemo 11 Days after one dose of 
Bevacizumab (Day 1) & two doses 
of Temsirolimus (Day 1 & Day 8)
PATIENT #27
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2) Patient #15, a 51-year old woman with rectal cancer metastatic to the lungs, bones and 
spleen was enrolled on dose level 3 (bevacizumab 15 mg/kg and temsirolimus 5 mg).  
The patient was admitted to the hospital on day 15 of the first cycle for failure to thrive, 
severe fatigue, nausea and abdominal pain.  She had only received cycle 1, day 1 therapy 
with bevacizumab and temsirolimus.  She did not receive cycle 1, day 8 temsirolimus 
secondary to severe fatigue.  During the hospital work-up, she was found to have a rectal 
stricture and stent was placed by gastroenterology on cycle 1, day 18.  The patient 
subsequently developed pseudo-obstruction and had a decompression tube placed by 
gastroenterology on cycle 1, day 29.  On cycle 1, day 31, she became hypotensive with 
blood pressures refractory to pressors and aggressive intravenous fluids.  She also had 
decreased hemoglobin on labs though no source of bleeding was identified.  The family 
opted for supportive measures only.  She died later the next day on cycle 1, day 32.   
3) Patient #32, a 55-year old woman with endometrial cancer metastatic to the peritoneum 
was enrolled on dose level 8 (bevacizumab 7.5 mg/kg and temsirolimus 25 mg).  On 
cycle 12, day 13 she was admitted to an outside hospital for severe abdominal pain.  She 
was found to have sepsis and peritonitis and died later that day on cycle 12, day 13 with 
supportive measures in place. 
 
Antitumor Activity 
      Forty-two of the 56 patients were measurable by RECIST (Figure 5).  Ten patients were 
assigned a value of 21% for clinical progression or new lesions.   Among the remaining four 
patients, three patients were assigned a value of 1% as they were evaluable but not measurable 
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per RECIST but had stable disease (+), and one patient (patient #27 shown in Figures 4a and 4b) 
had a remarkable clinical response but died before restaging evaluation was performed. 
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•42 of the 56 patients were measurable by RECIST
• 10 patients were assigned a value of 21% for clinical progression or new lesions (*)
• Among the remaining 4 patients:
• 3 patients were assigned a value of 1% as they were evaluable but not 
measurable per RECIST but had stable disease (+)
• 1 patient (#27) had a remarkable clinical response but died before restaging 
evaluation was performed
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Figure 5:  Best Response by RECIST 
 
      Five patients achieved a partial response (PR).  The details of each case are described below: 
1) Patient #21, a 60-year old woman with endometrial cancer metastatic to liver, pelvis, and 
pelvic lymph nodes, was enrolled on dose level 5 (bevacizumab 7.5 mg/kg and 
temsirolimus 12.5 mg).  The patient‟s previous treatments include:  surgery, carboplatin, 
Taxol, Doxil, EZN-2208 (pegylated irinotecan) and palliative radiation.  The patient had 
a PR of 39% and received treatment for 12 cycles (9 months).  Figure 5 illustrates the 
radiographic images of the patient. 
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2) Patient #24, a 33-year old woman with squamous cell carcinoma of the cervix, metastatic 
to the mediastinum and retroperitoneal lymph nodes, enrolled on dose level 6 
(bevacizumab 15 mg/kg and temsirolimus 12.5 mg).  The patient‟s previous treatments 
include: cisplatin, Taxol, radiation, brachytherapy, topotecan, Xeloda, and Tarceva. The 
patient had a PR of 43% and received treatment for 6 cycles (4.5 months).  Figures 7 and 
8 illustrate the radiographic images of the patient. 
3) Patient #29, a 51-year old woman with lymphangioleimyomatosis with lymph node 
involvement of the left supraclavicular, right retrocrural, aorto-pulmonary window, 
bilateral common iliac region, and left paraaortic and aortocaval space.  The patient was 
enrolled on dose level 7 (bevacizumab 2.5 mg/kg and temsirolimus 20 mg).  The patient 
had had multiple surgeries.  The patient had a PR of 68% and received 8 cycles (6 
months) of therapy on protocol.  The patient is still receiving treatment at home off-
protocol as the burden and expensive of travel became too much.  Figure 9 illustrates the 
radiographic images of the patient. 
4) Patient #44, a 70-year old woman with acinic cell carcinoma of the right cheek metastatic 
to the lungs and bone, enrolled on dose level 11 (bevacizumab 5 mg/kg and temsirolimus 
25 mg).  The patient‟s previous treatments include:  surgery, radiation, 
farnesyltransferase inhibitor (protocol ID98-369), carboplatin, Taxol, Benzimate 
Fungicide, FTS protocol (direct RAS inhibitor), patupilone, and AZD8330 (MEK 
inhibitor).  The patient had a PR of 30% and received treatment for 10 cycles (7.5 
months).  Figure 10 illustrates the radiographic images of the patient. 
5) Patient #57, a 49-year  old man with squamous cell carcinoma of the oral tongue 
metastatic to lymph nodes in the right neck, right supraclavicular fossa, mediastinum and 
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right axilla, enrolled on dose level 12 (bevacizumab 10 mg/kg and temsirolimus 25 mg).   
The patient‟s previous treatments include:  surgery, radiation,  Herceptin, Taxol, 
cisplatin, carboplatin, sorafenib, IMC-A12 (insulin growth factor receptor [IGFR] 
inhibitor), and OSI-906 (IGFR inhbititor). The patient had a PR of 35% and received 
treatment for 5 cycles (3.75 months).  Figure 11 illustrates the radiographic images of the 
patient. 
Table 10:  Partial Responses 
Pt 
# 
Tumor Type Dose 
Level 
Best 
Response 
Cycles 
Received 
21 Endometrial  5 -39% 12 
24 Cervical - Squamous 6 -43% 6 
29 Lymphangioleiomyomatosis 7 -68% 8+ 
44 Acinic Cell 11 -36% 10 
57 Oral Tongue - Squamous 12 -35% 5 
 
Partial Response in Patient #21
Segment V Liver
Baseline:  10/23/08 C4D16:  2/40/09
 
Figure 6: Partial Response in Patient #21, Segment V Liver  
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Partial Response in Patient #24
Aortocaval Lymph Node
Baseline:  12/29/08 C4D16:  4/23/09
 
Figure 7:  Partial Response in Patient #24, Aortocaval Lymph Node 
 
Partial Response in Patient #24
Left Common Iliac Lymph Node
Baseline:  12/29/08 C4D16:  4/23/09
 
Figure 8: Partial Response in Patient #24, Left Common Iliac Lymph Node 
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Partial Response in Patient #29
Para-aortic Lymph Node
Baseline:  2/18/09 C6D15:  6/26/09
 
Figure 9: Partial Response in Patient #29, Para-aortic Lymph Node 
 
Baseline:  6/22/09 C6D15:  11/3/09
Partial Response in Patient #44
Right Lower Lobe of Lung
  
Figure 10: Partial Response in Patient #44, Right Lower Lobe of Lung 
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Partial Response in Patient #57
Hypopharyngeal Mass
Baseline:  7/28/09 C4D15:  10/29/09
 
Figure 11:  Partial Response in Patient #57, Hypopharyngeal Mass 
 
      Stable disease lasting longer than six months was observed in 7 patients (13%) listed in table 
11 with details regarding the dose level, number of cycles received, and best response by 
RECIST.  Of all enrolled patients, the median cycles received was 4, the range was 1 to 14 
cycles.  Thirty-five patients (63%) received more than 2 cycles. 
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Table 11:  Stable Disease Lasting > 6 Months 
 
Pt 
# 
Tumor Type Dose 
Level 
Best 
Response 
Cycles 
Received 
Comments 
6 
Primary 
Peritoneal 
Carinoma 2 0% 8   
13 Ovarian 3 -7% 12   
17 Colorectal 4 -4% 14   
22 
Parotid 
Cancer 5 
Not 
measurable 12 Progressive disease in the lung 
31 Colorectal 7 -4% 8   
32 Endometrial 8 
Not 
measurable 12 
Died from non-neutropenic 
sepsis. 
34 
Parotid 
Cancer 8 0% 11 
Pt taken off study for clinical 
progression as evidenced by 
oropharyngeal bleeding from 
tumor. 
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Part V 
 
Conclusions, Discussion, and Future Directions
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 This phase I study of combined bevacizumab and temsirolimus successfully completed 
dose escalation to the highest specified dose level, dose level 13, which consisted of FDA-
approved doses of both drugs (bevacizumab 15 mg/kg and temsirolimus 25 mg).  Escalation 
beyond the FDA-approved doses was not included in this trial design because insurance 
companies would not be expected to reimburse the cost of the drugs above the FDA-approved 
doses.  No DLTs were observed at the highest dose level.  The recommended phase II dose for 
the combination is bevacizumab 15 mg/kg and temsirolimus 25 mg. 
 The study design was efficient and allowed for exploration of multiple dose levels.  My 
hypothesis that our new trial design would facilitate identification of more than one MTD was 
not achieved likely because the maximum dose of each targeted drug proved to be tolerable in 
combination due to non-overlapping toxicities.   Going forward, I have plans to apply this trial 
design in other investigator initiated protocols combining targeted agents. 
 Combination therapy with bevacizumab and temsirolimus showed safety and excellent 
tolerance.  Thirty-nine patients (70%) experienced no treatment-related toxicity greater than 
grade 2 and only one DLT was obtained throughout the trial.  A minority of patients, 17 patients 
(30%), experienced grade 3 or 4 toxicities, most of which were  cytopenias, dyslipidemia, 
elevated liver function tests (ALT/AST) or fatigue, and attributed to temsirolimus. 
 Partial responses were seen in five of 56 patients (9%) and stable disease lasting more 
than 6 months was seen in 7 patients (13%).  This is especially significant when taking  into 
consideration the extensive number of prior therapies of the patients involved in this study, 
including systemic therapy in 55 patients (98%) with the median number of prior systemic 
therapies at four, with a range of zero to 11.  Furthermore, 16 patients (29%) had previously 
received treatment on a phase I trial.   
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 Two of five (40%) of the patients with PRs were found to have either a 
phosphatidylinositol 3-kinase (PI3 kinase) mutation or loss of phosphatase and tensin homolog 
(PTEN).  None of the patients with stable disease lasting > 6 months were found to have PI3 
kinase mutations and PTEN loss analysis was not performed on any of these patients.  Please 
note that PTEN loss was recently added in September of 2009 as a Clinical Laboratory 
Improvement Amendments (CLIA)-certified, immunohistochemistry (ICH) test by the Pathology 
Department at M. D. Anderson Cancer Center.   
Mutations in PI3 kinase result in activation of the PI3 kinase/AKT/mTOR pathway 
(Figure 12) and are present in a variety of tumor types(36, 37).  Janku et al. recently published a 
response rate of 35% in heavily pretreated patients with somatic PI3 kinase mutations when 
treated with PI3kinase/AKT/mTOR pathway inhibitors(38).  Temsirolimus, as previously 
mentioned, is an mTOR inhibitor.  If we were to further evaluate mutational status and response 
the following is seen: 
 PI3 kinase mutation present/Total number of PI3 kinase mutations tested = 1/27 = 4%. 
 PTEN loss mutation present/Total number of PTEN loss mutations tested = 1/2 = 50%. 
  (CR/PR)/Total Patients = 5/56 = 9%. 
 (CR/PR + SD > 6 months)/Total patients = 12/56 = 21%. 
 (Total with CR/PR + SD > 6 months) AND (PI3 kinase mutation present OR PTEN 
loss)/(Total with CR/PR + SD > 6 months) = 2/12 = 17%. 
 (Total with CR/PR + SD > 6 months) AND (PI3 kinase mutation present OR PTEN 
loss)/(Total with PI3 kinase mutation OR PTEN loss) = 2/2=100% 
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To summarize, 40% of patients with CR/PR and 17% of patients with SD > 6 months and CR/PR 
had PI3 kinase mutation or PTEN loss.  Of those tested for PI3 kinase mutation or PTEN loss 
and who showed positivity for either test, 100% had CR/PR or SD > 6 months.   
The protocol was written to allow us to expand enrollment by a total of 14 patients with a 
tumor type where response, as defined by one or more of the following:  1) stable disease for 
more than or equal to four months, 2) decrease in the sum of target lesions by more than or equal 
to 20% by RECIST criteria, or 3) decrease in tumor markers by more than or equal to 25%, is 
seen.  Based on the results of this trial summarized in Table 14, we have expanded enrollment to 
patients with squamous cell of the head and neck, parotid cancer, endometrial cancer, cervical 
cancer, colorectal cancer, ovarian/primary peritoneal/fallopian tube cancer, acinic cell 
carcinoma/salivary gland cancer and lymphangioleiomyomatosis.  
In conclusion, the combination of bevacizumab and temsirolimus is well tolerated and 
has demonstrated clinical activity in patients with advanced malignancy having undergone 
extensive prior therapy.  Because partial responses and prolonged stable disease (SD > 6 months) 
have been seen in a variety of tumor types (as above), further evaluation in these tumor types at 
the recommended phase II dose is warranted.   Additionally, it will be interesting to evaluate the 
incidence of PI3 kinase mutations or PTEN loss and correlate this with response to this therapy.   
 
Table 12:  Partial Responses and Mutation Status 
 
Pt 
# 
Tumor Type Dose 
Level 
Best 
Response 
Cycles 
Received 
PTEN 
Loss 
PI3 
Kinase 
Mutation 
RAS 
Mutation 
RAF 
Mutation 
21 Endometrial  5 -39% 12 ND Y ND ND 
24 Cervical - Squamous 6 -43% 6 ND N ND ND 
29 Lymphangioleiomyomatosis 7 -68% 8+ ND N ND ND 
44 Acinic Cell 11 -36% 10 ND N ND ND 
57 Oral Tongue - Squamous 12 -35% 5 Y N ND N 
 
ND = not done; N = No; Y= Yes 
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Table 13:  Stable Disease Lasting > 6 Months and Mutation Status 
 
Pt 
# 
Tumor Type Dose 
Level 
Best Response Cycles 
Received 
PTEN 
Loss 
PI3 Kinase 
Mutation 
RAS 
Mutation 
RAF 
Mutation 
6 
Primary 
Peritoneal 
Carinoma 2 0% 8 ND N ND ND 
13 Ovarian 3 -7% 12 ND N ND ND 
17 Colorectal 4 -4% 14 ND N ND ND 
22 Parotid Cancer 5 
Not 
Measurable 12 ND N ND ND 
31 Colorectal 7 -4% 8 ND N Y ND 
32 Endometrial 8 
Not 
Measurable 12 ND N N ND 
34 Parotid Cancer 8 0% 11 ND N ND ND 
 
ND = not done; N = No; Y= Yes 
 
 
Table 14:  Stable Disease Lasting > 6 Months or Partial Remissions by Tumor 
Type 
 
Tumor Type SD> 6 
months or 
PR (N) 
Total Treated 
(N) 
Percent 
Response (%) 
Endometrial  2 4 50 
Cervical - Squamous 1 2 50 
Lymphangioleiomyomatosis 1 1 100 
Acinic Cell 1 1 100 
Oral Tongue - Squamous 1 1 100 
Ovarian 2 6 33 
Colorectal 2 10 20 
Parotid Cancer 2 2 100 
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Figure 12:  PI3 kinase/AKT/mTOR pathway 
 
 
 
 
 
50 
 
 
 
 
 
 
 
 
 
Part VI 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
REFERENCES 
 
1. Phase I Combination Template Version 5.0 (MS Word). 
  
In http://ctep.cancer.gov/protocolDevelopment/docs/ph1_comb_temp.doc. 
 
2. 1985. EORTC guidelines for phase I trials with single agents in adults. EORTC New  
 
Drug Development Committee. Eur J Cancer Clin Oncol 21:1005-1007. 
 
3. Carter, S. K. 1977. Clinical trials in cancer chemotherapy. Cancer 40:544-557. 
 
4. Eisenhauer, E., Twelves, C., Buyse, M. 2006. Phase I Cancer Clinical Trials A Practical  
 
Guide. Oxford Medical Publications. 
 
5. Korn, E. L., and R. Simon. 1993. Using the tolerable-dose diagram in the design of phase  
 
I combination chemotherapy trials. J Clin Oncol 11:794-801. 
 
6. Beaudry, P., J. Force, G. N. Naumov, A. Wang, C. H. Baker, A. Ryan, S. Soker, B. E.  
 
Johnson, J. Folkman, and J. V. Heymach. 2005. Differential effects of vascular  
 
endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial  
 
progenitors and mature circulating endothelial cells: implications for use as a surrogate  
 
marker of antiangiogenic activity. Clin Cancer Res 11:3514-3522. 
 
7. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med  
 
285:1182-1186. 
 
8. Hicklin, D. J., and L. M. Ellis. 2005. Role of the vascular endothelial growth factor  
 
pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027. 
 
9. Rowe, D. H., J. Huang, M. L. Kayton, R. Thompson, A. Troxel, K. M. O'Toole, D.  
 
Yamashiro, C. J. Stolar, and J. J. Kandel. 2000. Anti-VEGF antibody suppresses primary  
 
tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg  
 
35:30-32; discussion 32-33. 
 
52 
 
10. Carmeliet, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69  
 
Suppl 3:4-10. 
 
11. Ferrara, N., K. J. Hillan, and W. Novotny. 2005. Bevacizumab (Avastin), a humanized  
 
anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun  
 
333:328-335. 
 
12. Ferrara, N. 2005. VEGF as a therapeutic target in cancer. Oncology 69 Suppl 3:11-16. 
 
13. Ferrara, N., and R. S. Kerbel. 2005. Angiogenesis as a therapeutic target. Nature  
 
438:967-974. 
 
14. Adjei, A. A., and M. Hidalgo. 2005. Intracellular signal transduction pathway proteins as  
 
targets for cancer therapy. J Clin Oncol 23:5386-5403. 
 
15. Baselga, J., and C. L. Arteaga. 2005. Critical update and emerging trends in epidermal  
 
growth factor receptor targeting in cancer. J Clin Oncol 23:2445-2459. 
 
16. Blagosklonny, M. V. 2001. Hypoxia-inducible factor: Achilles' heel of antiangiogenic  
 
cancer therapy (review). Int J Oncol 19:257-262.\ 
 
17. Blagosklonny, M. V. 2004. Antiangiogenic therapy and tumor progression. Cancer Cell  
 
5:13-17. 
 
18. Choi, K. S., M. K. Bae, J. W. Jeong, H. E. Moon, and K. W. Kim. 2003. Hypoxia- 
 
induced angiogenesis during carcinogenesis. J Biochem Mol Biol 36:120-127. 
 
19. Lee, J. W., S. H. Bae, J. W. Jeong, S. H. Kim, and K. W. Kim. 2004. Hypoxia-inducible  
 
factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36:1-12. 
 
20. Linehan, W. M., M. M. Walther, and B. Zbar. 2003. The genetic basis of cancer of the  
 
kidney. J Urol 170:2163-2172. 
 
21. Powis, G., and L. Kirkpatrick. 2004. Hypoxia inducible factor-1alpha as a cancer drug  
 
53 
 
target. Mol Cancer Ther 3:647-654. 
 
22. Tee, A. R., and J. Blenis. 2005. mTOR, translational control and human disease. Semin  
 
Cell Dev Biol 16:29-37. 
 
23. Tsuzuki, Y., D. Fukumura, B. Oosthuyse, C. Koike, P. Carmeliet, and R. K. Jain. 2000.  
 
Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible  
 
factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates  
 
vascular response and growth rate in tumors. Cancer Res 60:6248-6252. 
 
24. Welsh, S. J., and G. Powis. 2003. Hypoxia inducible factor as a cancer drug target. Curr  
 
Cancer Drug Targets 3:391-405. 
 
25. Yu, J. L., J. W. Rak, B. L. Coomber, D. J. Hicklin, and R. S. Kerbel. 2002. Effect of p53  
 
status on tumor response to antiangiogenic therapy. Science 295:1526-1528. 
 
26. Zhong, H., A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler,  
 
W. B. Isaacs, G. L. Semenza, and J. W. Simons. 1999. Overexpression of hypoxia- 
 
inducible factor 1alpha in common human cancers and their metastases. Cancer Res  
 
59:5830-5835. 
 
27. Kapoor, A. 2009. Inhibition of mTOR in kidney cancer. Curr Oncol 16 Suppl 1:S33-39. 
 
28. Rai, J. S., M. J. Henley, and H. L. Ratan. Mammalian target of rapamycin: a new target in  
 
prostate cancer. Urol Oncol 28:134-138. 
 
29. Torisel Kit (temsirolimus) Prescribing Information, Wyeth Pharmaceuticals Inc. 
 
30. Del Bufalo, D., L. Ciuffreda, D. Trisciuoglio, M. Desideri, F. Cognetti, G. Zupi, and M.  
 
Milella. 2006. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor  
 
temsirolimus. Cancer Res 66:5549-5554. 
 
31. Hudes, G., M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska,  
 
54 
 
J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I. G. Schmidt-Wolf, O.  
 
Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, and R. J. Motzer. 2007.  
 
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med  
 
356:2271-2281. 
 
32. Huang, X., S. Biswas, Y. Oki, J. P. Issa, and D. A. Berry. 2007. A parallel phase I/II  
 
clinical trial design for combination therapies. Biometrics 63:429-436. 
 
33. MDACC Study Summary 2007-0668.  Retrieved May 24, 2010. . In  
 
http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2007-0668. 
 
34. Falchook, G. 2009. Hypoxia-Inducible Factor-1a (HIF-1a) Modulation in Combination  
 
with Anti-Angiogenic Therapy. 
 
35. Therasse, P., S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J.  
 
Verweij, M. Van Glabbeke, A. T. van Oosterom, M. C. Christian, and S. G. Gwyther.  
 
2000. New guidelines to evaluate the response to treatment in solid tumors. European  
 
Organization for Research and Treatment of Cancer, National Cancer Institute of the  
 
United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216. 
 
36. Engelman, J. A. 2009. Targeting PI3K signalling in cancer: opportunities, challenges and  
 
limitations. Nat Rev Cancer 9:550-562. 
 
37. Luo, J., B. D. Manning, and L. C. Cantley. 2003. Targeting the PI3K-Akt pathway in  
 
human cancer: rationale and promise. Cancer Cell 4:257-262. 
 
38. Janku F., I. Garrido-Laguna, D. S. Hong, A. M. Tsimberidou, A. Naing, G. S. Falchook,  
 
J. J. Wheler, SL Moulder, S Fu, S Piha-Paul, R Kurzrock.  PIK3CA mutations in patients  
 
with advanced cancers treated in phase I clinical trials. . In: AACRNCI-EORTC  
 
Molecular Targets and Cancer Therapeutics Conference. Boston, MA, USA; 2009:208. 
 
55 
 
 
 
 
 
 
 
 
 
 
Part VII 
 
Appendices  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Appendix 1: Scales for Performance Status Evaluation 
 
 
                       ECOG Performance Status (94) 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able 
to carry out work of a light or sedentary nature, e.g., light house 
work, office work 
2 Ambulatory and capable of all selfcare but unable to carry out any 
work activities. Up and about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 
50% of waking hours 
4 Completely disabled. Cannot carry on any selfcare. Totally confined 
to bed or chair 
5 Dead 
  
    
Karnofsky Performance Status Scale                                                                       
Definitions Rating (%) Criteria (95) 
Able to carry on 
normal activity and 
100 Normal no complaints; no evidence of disease. 
to work; no special 
care needed. 
90 Able to carry on normal activity; minor signs or symptoms of disease.  
  
80 Normal activity with effort; some signs  or symptoms of disease.  
Unable to work; able 
to live at home 
70 Cares for self; unable to carry on normal activity or to do active work. 
and care for most 
personal needs; 
60 
Requires occasional assistance, but is able to care for most of his 
personal needs. 
varying amount of 
assistance needed. 
50 Requires considerable assistance and frequent medical care. 
Unable to care for  
40 Disabled; requires special care and assistance. 
self; requires 
equivalent of 30 
Severely disabled; hospital admission is indicated although death not 
imminent.  
 institutional or 
hospital care;  
20 
Very sick; hospital admission necessary; active supportive treatment 
necessary. 
disease may be 
progressing rapidly. 
10 Moribund; fatal processes progressing rapidly. 
 
0 Dead 
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Appendix 2: Permission to Use HIF-1α Pathway Figure 
 
 
From: Gillette,Lysaann N  
Sent: Thursday, July 22, 2010 8:43 AM 
To: 'daniel.peet@adelaide.edu.au' 
Cc: Piha-Paul,Sarina Anne 
Subject: RE: Request for permission to use HIF1 figure 
 
Dr. Peet, 
 
I do thank you for the quick reply. My physician’s name is Dr. Sarina Piha-Paul , the nature is that she is defending her thesis 
to get her Masters degree, and the title of the thesis is An Innovative Phase I Trial Design Allowing for the Identification of 
Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents. Again, I thank you for 
allowing us to use your HIF1 figure.  
 
 
Lysaann Gillette                                                                                                                                 
Administrative Assistant to: 
Siqing Fu, MD, PhD 
Sarina Piha-Paul, MD 
UT M.D. Anderson Cancer Center 
Division of Cancer Medicine 
Department of Investigational Cancer Therapeutics 
1515 Holcombe Boulevard, Unit 455 
Houston, Texas 77030 
Phone (713) 745-0147  
Fax (713) 745-3855 
 
 
From: Daniel Peet [mailto:daniel.peet@adelaide.edu.au]  
Sent: Wednesday, July 21, 2010 5:55 PM 
To: Gillette,Lysaann N 
Subject: RE: Request for permission to use HIF1 figure 
 
Dear Lysaann, 
 
Yes, I am happy for the physician to use this figure in their thesis. Could you please first inform me of the name of the physician 
and also the nature and title of the thesis? Please just acknowledge that the figure is used with my permission (my details 
below, although they don’t all need to be included). 
 
Best Regards, 
 
Dan 
 
---------------------------------------------------------- 
Dan Peet, PhD 
Senior Lecturer 
School of Molecular and Biomedical Science,  
University of Adelaide  
Adelaide,  SA,  5005  
AUSTRALIA 
 
Email:  daniel.peet@adelaide.edu.au 
Ph:     +61 8 8303 5367 
Fax:    +61 8 8303 4362 
CRICOS Provider Number 00123M 
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From: Gillette,Lysaann N [mailto:lgillette@mdanderson.org]  
Sent: Thursday, 22 July 2010 7:16 AM 
To: 'daniel.peet@adelaide.edu.au' 
Cc: Piha-Paul,Sarina Anne 
Subject: Request for permission to use HIF1 figure 
 
Dr. Daniel Peet,  
  
I'm writing in hopes that you will be able to assist me at your earliest convenience before July 23, 2010. My physician found 
a figure of the HIF1 in the following link below and would like to have permission to use it in her thesis and would like to 
know how to properly credit and reference you. Would you kindly assist? I do thank you.  
  
http://www.google.com/imgres?imgurl=http://www.adelaide.edu.au/mbs/research/peet/images/Basic_HIF2.jpg&imgrefurl=
http://www.adelaide.edu.au/mbs/research/peet/&usg=__f6kG2LKT5Yvb5pAxoQUxAM3sWl4=&h=604&w=600&sz=78&hl=e
n&start=21&sig2=1ZSCfYKN0Od2eljRp3ZA2w&um=1&itbs=1&tbnid=VWcQ7iGvohjHPM:&tbnh=135&tbnw=134&prev=/images
%3Fq%3DHIF%2B1%26start%3D20%26um%3D1%26hl%3Den%26sa%3DN%26rlz%3D1T4GGLL_enUS338US338%26ndsp%3D20%26tbs
%3Disch:1&ei=m2hHTLeuNISdlgfLkpzuAw 
  
  
Lysaann Gillette                                                                                                                                 
Administrative Assistant to: 
Siqing Fu, MD, PhD 
Sarina Piha-Paul, MD 
UT M.D. Anderson Cancer Center 
Division of Cancer Medicine 
Department of Investigational Cancer Therapeutics 
1515 Holcombe Boulevard, Unit 455 
Houston, Texas 77030 
Phone (713) 745-0147  
Fax (713) 745-3855 
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Appendix 3: Permission to Use Illustration of Combination Doses Figure 
 
 
From: Gillette,Lysaann N  
Sent: Thursday, July 29, 2010 10:32 AM 
To: Berry,Donald; Huang,Xuelin 
Cc: Piha-Paul,Sarina Anne 
Subject: RE: Request for permission to use An Illustration of Combination Doses 
 
Dr. Berry and Dr. Huang, 
 
On behalf of Dr. Piha-Paul, I would like to thank you for granting her permission to use your illustration.  
 
Lysaann Gillette                                                                                                                                 
Administrative Assistant to: 
Siqing Fu, MD, PhD 
Sarina Piha-Paul, MD 
UT M.D. Anderson Cancer Center 
Division of Cancer Medicine 
Department of Investigational Cancer Therapeutics 
1515 Holcombe Boulevard, Unit 455 
Houston, Texas 77030 
Phone (713) 745-0147  
Fax (713) 745-3855 
 
From: Berry,Donald  
Sent: Wednesday, July 28, 2010 8:20 PM 
To: Gillette,Lysaann N 
Cc: Huang,Xuelin; Piha-Paul,Sarina Anne 
Subject: Re: Request for permission to use An Illustration of Combination Doses 
 
She has our permission. Don Berry 
 
 
 
From: Gillette,Lysaann N  
Sent: Wednesday, July 28, 2010 4:37 PM 
To: Berry,Donald; Huang,Xuelin 
Cc: Piha-Paul,Sarina Anne 
Subject: Request for permission to use An Illustration of Combination Doses 
 
Dr. Donald Berry and Dr. Xuelin Huang, 
  
I'm writing in hopes that you will be able to assist me at your earliest convenience before July 30, 2010. Dr. Piha-Paul would like 
to have permission to use your Illustration of Combination Doses (as shown below) in her thesis and would like to know how to 
properly credit and reference you. Would you kindly assist? I do thank you. 
  
 
       
 
 
 
 
 
 
 
 
 
60 
 
An Illustration of Combination Doses 
 
 
 
 
Lysaann Gillette                                                                                                                                 
Administrative Assistant to: 
Siqing Fu, MD, PhD 
Sarina Piha-Paul, MD 
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Appendix 4: Phase I Combination Template Instructions 
 
The protocol template is a tool to facilitate rapid protocol development.  It is not intended to 
supersede the role of the Protocol Chair in the authoring and scientific development of the 
protocol.  It contains the “boilerplate” language commonly required in protocols submitted to 
CTEP.  All sections may be modified as necessary to meet the scientific aims of the study and 
development of the protocol.   
 
1. Each protocol template consists of two parts:  
 
a) Protocol Submission Worksheet:  available at 
http://ctep.cancer.gov/protocolDevelopment/docs/psw.doc.  This document contains 
prompts for required administrative information.  
 
b) Main Body and Appendices of the protocol:  attached below.  This document 
provides standard language plus instructions and prompts for information. 
 
2. The Protocol Submission Worksheet and Protocol Template documents should be 
completed, and both documents (including the Appendices) should be submitted to CTEP 
for review. 
 
3. All sections in the Protocol Template should be retained to facilitate rapid review.  If not 
appropriate for a given study, please insert “Not Applicable” after the section number and 
delete unneeded text. 
 
4. All protocol template instructions and prompts are in italics.  Blank space or ________ 
indicates that you should fill in the appropriate information.  As you complete the 
information requested, please delete the italicized text. 
 
5. Please redline, highlight or underline new or modified text as this will facilitate rapid 
review. 
 
6. For problems or questions encountered when using these documents (Protocol 
Submission Worksheet or Protocol Template), please contact the CTEP help desk by 
telephone (301-840-8202), fax (301-948-2242), or e-mail 
(ncictephelp@ctep.nci.nih.gov). 
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NCI Protocol #: To be assigned by the NCI.  For cooperative group studies, the NCI will 
utilize the local group protocol #. 
 
Local Protocol #: Please insert your local protocol # for this study. 
 
TITLE:  A Phase 1 Study of   CTEP IND Agent   in Combination with 
Other Agent(s)    in    Solid Tumors/Study Disease 
 
Use Simplified Disease Classification (SDC) terminology for study disease.  Please refer to the 
CTEP Web site (http://ctep.cancer.gov/protocolDevelopment/codes_values.htm) for a complete 
list of SDC disease terms. 
 
Coordinating Center: Name of Organization (If this is a multi-institution study, only one 
organization/institution can be the coordinating center.) 
 
*Principal Investigator: Name 
 Address 
 Address 
 Telephone 
 Fax 
 e-mail address 
 
Co-Investigators: Name 
 Address 
 Address 
 Telephone 
 Fax 
 e-mail address 
 
 Name 
 Address 
 Address 
 Telephone 
 Fax 
 e-mail address 
 
*A study can have only one Principal Investigator.  The Principal Investigator must be a 
physician and is responsible for all study conduct.  Please refer to the Investigator's Handbook 
on the CTEP Web site for a complete description of the Principal Investigator's responsibilities 
(http://ctep.cancer.gov/investigatorResources/default.htm#Investigators_handbook). 
 
The Principal Investigator and all physicians responsible for patient care must have a current 
FDA Form 1572, Supplemental Investigator Data Form (SIDF), Financial Disclosure Form 
(FDF), and CV on file with the NCI.  Failure to register all appropriate individuals could delay 
protocol approval.  If you are unsure of an investigator's status, please contact the 
Pharmaceutical Management Branch, CTEP at (301) 496-5725 or by e-mail at 
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PMBRegPend@ctep.nci.nih.gov.  Please indicate, on the title page, if an Associate Investigator 
is NOT responsible for patient care and therefore does not require a current 1572, SIDF, FDF, 
and CV on file.  
 
If this is a multi-institution study, the protocol title page should include the name of each 
participating institution, the investigator responsible for the study at that institution, and his/her 
phone # and e-mail address.  (This requirement does not apply to Cooperative Group studies.) 
 
If this study includes an investigational agent supplied by the NCI Division of Cancer Treatment 
and Diagnosis and will involve a Canadian institution(s), a Clinical Trials Application (CTA) 
will need to be submitted to the Canadian Health Products and Food Branch (HPFB) for their 
participation in the study.  A Canadian investigator should be designated to be responsible for 
preparing and submitting the CTA to the Canadian HPFB for the Canadian institution(s).  
Procedures and forms for preparing and submitting a CTA to the Canadian HPFB are available 
at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clini/cta_application-
eng.php.  A copy of the “No Objection” letter should be forwarded to the Pharmaceutical 
Management Branch at (fax) 301-402-0429 when available. 
 
Statistician: Study Coordinator: 
(if applicable) (if applicable) 
 Name Name 
 Address Address 
 Address Address 
 Telephone Telephone 
 Fax Fax 
 e-mail address e-mail address 
 
 
Responsible Research Nurse: Responsible Data Manager: 
 Name Name 
 Address Address 
 Address Address 
 Telephone Telephone 
 Fax Fax 
 e-mail address e-mail address 
 
NCI Supplied Agent(s):   CTEP IND Agent (NSC #; IND #, if available)   
 
Please list agent name, NSC #, IND #, and supplier(s) of any other investigational agent(s). 
 
Please list all commercially available agents and their suppliers.  
 
Protocol Type / Version # / Version Date: ___Type / Version # / Version Date____ 
 
(Protocol types:  Original, Revision, or Amendment) 
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SCHEMA 
 
Please provide a schema for the study.  If preferred, a summary or synopsis may be provided. 
 
 
Dose Escalation Schedule 
Dose Level 
Dose* 
Agent X 
(units) 
Agent Y 
(units) 
Agent Z 
(units) 
Level 1    
Level 2    
Level 3    
Level 4    
Level 5    
*Doses are stated as exact dose in units (e.g., mg/m
2
, mcg/kg, etc.) rather than as 
a percentage. 
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1. OBJECTIVES 
 
 1.1. Primary Objectives 
 
Please insert primary protocol objectives. 
 
 1.2. Secondary Objectives 
 
Please insert secondary protocol objectives, if pertinent. 
 
 
2. BACKGROUND 
 
 2.1  CTEP-Supplied Investigational Agent(s) 
 
Please provide background information below on each CTEP-supplied 
investigational study agent, including information to support safety issues and the 
rationale for the proposed starting dose, dose escalation scheme, and regimen 
chosen.  Please also provide information on the mechanism of action, summaries of 
nonclinical and clinical studies, nonclinical and clinical pharmacokinetics, and 
major route of elimination.  If available, please include information on the 
metabolism of the study agent in humans and its potential for drug interactions (e.g., 
via the P450 enzyme system).  
 
2.1.1 CTEP IND Agent #1 
 
2.1.2 CTEP IND Agent #2 
 
 2.2  Other Agent(s) 
 
Please provide background information on other agent(s) and/or treatments in this 
study, including information to support safety issues and the rationale for the 
proposed starting dose and dose escalation scheme, if applicable. 
 
 2.3  Study Disease 
 
For disease-specific studies, please provide background information on the study 
disease. 
 
 2.4  Rationale 
 
Please provide the background and rationale for this combination therapy (in this 
disease). 
 
 2.5  Correlative Studies Background 
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Please provide background information on each planned correlative study including 
the biologic rationale and hypothesis as well as the relevant preclinical and clinical 
(if available) data.  Refer to “Guidelines for Correlative Studies in Clinical Trials” 
(http://ctep.cancer.gov/protocolDevelopment/templates_applications.htm).  If this 
trial includes no correlative studies, this section should be marked “N/A”. 
 
 
3. PATIENT SELECTION 
 
 3.1  Eligibility Criteria  
 
3.1.1 Patients must have histologically confirmed malignancy that is metastatic or 
unresectable and for which standard curative or palliative measures do not exist or 
are no longer effective. 
 
OR 
 
Patients must have histologically or cytologically confirmed   Study Disease  .  
Please specify eligible disease(s)/stage(s) using the CTEP Simplified Disease 
Classification (http://ctep.cancer.gov/protocolDevelopment/codes_values.htm). 
 
3.1.2 Please state allowable type and amount of prior therapy.  Define as appropriate 
any limitations on prior therapy and the time from last prior regimen (e.g., no 
more than 6 cycles of an alkylating agent; no more than 450 mg/m
2
 doxorubicin 
for agents with expected cumulative cardiotoxicity).  Include separate definitions 
for duration as needed (e.g., at least 4 weeks since prior chemotherapy or 
radiation therapy, 6 weeks if the last regimen included BCNU or mitomycin C).  
Include site/total dose for prior radiation exposure as needed (e.g., no more than 
3000 cGy to fields including substantial marrow). 
 
3.1.3 Age >18 years.  Please state reason for age restriction.  If applicable, the 
following text can be used.   
 
Because no dosing or adverse event data are currently available on the use of     
CTEP IND Agent    in combination with   [other agents]   in patients <18 years of 
age, children are excluded from this study, but will be eligible for future pediatric 
phase 1 combination trials. 
 
3.1.4 ECOG performance status <2 (Karnofsky >60%, see Appendix A). 
 
3.1.5 Life expectancy of greater than    [#weeks or months] . 
 
3.1.6 Patients must have normal organ and marrow function as defined below: 
 
 leukocytes >3,000/mcL 
 absolute neutrophil count >1,500/mcL 
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 platelets >100,000/mcL 
 total bilirubin within normal institutional limits 
 AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal 
 creatinine within normal institutional limits 
 OR 
 creatinine clearance >60 mL/min/1.73 m
2
 for patients with 
 creatinine levels above institutional normal. 
 
3.1.7 Please insert other appropriate eligibility criteria. 
 
3.1.8 Please use or modify the following paragraph as appropriate. 
 
The effects of    CTEP IND Agent    on the developing human fetus are unknown.  
For this reason and because   Agent Class   agents as well as other therapeutic 
agents used in this trial are known to be teratogenic, women of child-bearing 
potential and men must agree to use adequate contraception (hormonal or barrier 
method of birth control; abstinence) prior to study entry and for the duration of 
study participation.  Should a woman become pregnant or suspect she is pregnant 
while she or her partner is participating in this study, she should inform her 
treating physician immediately. 
 
3.1.9 Ability to understand and the willingness to sign a written informed consent 
document. 
 
 3.2  Exclusion Criteria 
 
3.2.1 Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for 
nitrosoureas or mitomycin C) prior to entering the study or those who have not 
recovered from adverse events due to agents administered more than 4 weeks 
earlier. 
 
3.2.2 Patients may not be receiving any other investigational agents. 
 
3.2.3 Patients with known brain metastases should be excluded from this clinical trial 
because of their poor prognosis and because they often develop progressive 
neurologic dysfunction that would confound the evaluation of neurologic and 
other adverse events. 
 
3.2.4 History of allergic reactions attributed to compounds of similar chemical or 
biologic composition to   CTEP IND Agent(s)   or other agents used in study. 
 
3.2.5 Please state appropriate exclusion criteria relating to concomitant medications or 
substances that have the potential to affect the activity or pharmacokinetics of the 
study agent(s).  Examples of such agents or substances include those that interact 
through the CYP450 isoenzyme system or other sources of drug interactions (e.g., P-
glycoprotein).  Specifically excluded substances may be listed below, stated in 
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Section 8 (Pharmaceutical Information), and presented as an appendix.  If appropriate, 
the following text concerning CYP450 interactions may be used or modified.   
 
Patients receiving any medications or substances that are inhibitors or inducers of 
specify CYP450 enzyme(s) are ineligible.  Lists including medications and 
substances known or with the potential to interact with the specified CYP450 
enzyme(s)  isoenzymes are provided in Appendix (#/letter. 
 
3.2.6 Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that would limit compliance 
with study requirements. 
 
3.2.7 The investigator(s) must state a medical or scientific reason if pregnant or 
nursing patients will be excluded from the study.  The full text of the Policies, 
Guidelines, and Procedures pertinent to this requirement is available on the 
CTEP Web site 
(http://ctep.cancer.gov/protocolDevelopment/policies_pregnant.htm).  Suggested 
text is provided below: 
 
Pregnant women are excluded from this study because CTEP IND Agent  is a/an 
Agent Class   agent with the potential for teratogenic or abortifacient effects.  
Because there is an unknown but potential risk for adverse events in nursing 
infants secondary to treatment of the mother with   CTEP IND Agent  , 
breastfeeding should be discontinued if the mother is treated with    CTEP IND 
Agent  .  These potential risks may also apply to other agents used in this study. 
 
3.2.8 The investigator(s) must state a medical or scientific reason if patients who are 
cancer survivors or those who are HIV positive will be excluded from the study.  
The full text of the Policies, Guidelines, and Procedures pertinent to this 
requirement is available on the CTEP Web site 
(http://ctep.cancer.gov/protocolDevelopment/policies_hiv.htm).  Suggested text is 
provided below: 
 
HIV-positive patients on combination antiretroviral therapy are ineligible because 
of the potential for pharmacokinetic interactions with _CTEP IND   Agent__.  In 
addition, these patients are at increased risk of lethal infections when treated with 
marrow-suppressive therapy.  Appropriate studies will be undertaken in patients 
receiving combination antiretroviral therapy when indicated. 
 
3.2.9 Please insert other appropriate agent-specific exclusion criteria. 
 
 3.3  Inclusion of Women and Minorities 
 
Both men and women of all races and ethnic groups are eligible for this trial.   
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REGISTRATION PROCEDURES 
 
This section should be marked “N/A” if this study is being performed within a single 
institution.  For multi-institutional studies, suggested text is provided below which may 
be modified as necessary.  Appropriate forms for the study (e.g., Eligibility Screening 
Worksheet, Registration Form) should be developed and included with the protocol.  
These forms must be used by all participating institutions for data submission. 
 
 4.1  General Guidelines 
 
Eligible patients will be entered on study centrally at the __(Coordinating Center) by 
the Study Coordinator.  All sites should call the Study Coordinator  ___(Telephone 
#)__ to verify dose level availabilities.  The required forms [Name of Form(s)] can be 
found in Appendix _(Appendix #)_. 
 
Following registration, patients should begin protocol treatment within 72 hours.  
Issues that would cause treatment delays should be discussed with the Principal 
Investigator.  If a patient does not receive protocol therapy following registration, the 
patient‟s registration on the study may be canceled.  The Study Coordinator should be 
notified of cancellations as soon as possible. 
 
Except in very unusual circumstances, each participating institution will order 
DCTD-supplied agents directly from CTEP.  Agents may be ordered by a 
participating site only after the initial IRB approval for the site has been forwarded by 
the Coordinating Center to the CTEP PIO (PIO@ctep.nci.nih.gov) except for Group 
studies. 
 
 4.2  Registration Process 
 
To register a patient, the following documents should be completed by the research 
nurse or data manager and faxed _ (Fax # )   or e-mailed _(e-mail address)_ to the 
Study Coordinator: 
 Copy of required laboratory tests 
 Signed patient consent form 
 HIPAA authorization form 
 Other appropriate forms (e.g., Eligibility Screening Worksheet, Registration 
Form)  
 
The research nurse or data manager at the participating site will then call _(Telephone 
#)_ or e-mail (e-mail address) the Study Coordinator to verify eligibility.  To 
complete the registration process, the Coordinator will 
 assign a patient study number 
 assign the patient a dose 
 register the patient on the study 
 fax or e-mail the patient study number and dose to the participating site 
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call the research nurse or data manager at the participating site and verbally confirm registration. 
 
 
5. TREATMENT PLAN 
 
 5.1  Agent Administration 
 
Treatment will be administered on an   inpatient/outpatient   basis.  Reported adverse 
events and potential risks for   CTEP IND Agent(s)   and   Other Agent(s)  are 
described in Section 7.  Appropriate dose modifications for   CTEP IND Agent(s)   
and   Other Agent(s)  are described in Section 6.  No investigational or commercial 
agents or therapies other than those described below may be administered with the 
intent to treat the patient's malignancy. 
 
State the starting dose of each agent and describe the dose escalation scheme and 
treatment regimen.  Use exact doses rather than percentages.  If appropriate, a table 
may be used to describe the regimen; see an example below.  Please refer to the 
CTEP Web site 
(http://ctep.cancer.gov/protocolDevelopment/policies_nomenclature.htm) for 
Guidelines for Treatment Regimen Nomenclature and Expression. 
 
Dose-Escalation Schedule 
Dose Level 
Dose* 
Agent X 
(units) 
Agent Y 
(units) 
Agent Z 
(units) 
Level 1    
Level 2    
Level 3    
Level 4    
Level 5    
*Doses are stated as exact dose in units (e.g., mg/m
2
, mcg/kg, etc.) rather than as 
a percentage. 
 
Example: 
 
REGIMEN DESCRIPTION 
Agent 
Premedications; 
Precautions 
Dose Route Schedule 
Cycle 
Length 
Agent X 
Premedicate 
with 
dexamethasone 
for 3 days prior 
to _Agent X_. 
**  in 500 
cc NS 
IV over 2 hours 
before Agent Y 
Days 1-3, 
week 1 
28 days 
(4 weeks) 
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4.
 Age
nt Y 
Avoid exposure 
to cold (food, 
liquids, air) for 
24 hr after each 
dose. 
**  in 250 
cc D5W 
IV 1 hr after 
completion of 
Agent A 
through 
separate IV line 
Days 1-3, 
week 1 
 
Agent Z Take with food. **  tablet PO in the a.m. 
Daily, 
weeks 1 
and 2 
**  Doses as appropriate for assigned dose level. 
 
5.1.1 CTEP IND Agent(s) 
 
Please describe in detail any prophylactic or supportive care regimens required 
for investigational study agent(s) administration and state any special 
precautions or relevant warnings (e.g., incompatibility of agent with commonly 
used intravenous solutions, necessity of administering agent(s) with food, 
premedications, etc.). 
 
5.1.2 Other Agent(s) 
 
Please describe in detail any prophylactic or supportive care regimens required 
for administration of each other agent in the treatment and state any special 
precautions or relevant warnings (e.g., incompatibility of agent with commonly 
used intravenous solutions, necessity of administering agent with food, 
premedications, etc.). 
 
5.1.3 Other Modality(ies) or Procedures 
 
Please provide a detailed description of any other modalities (e.g., surgery, 
radiotherapy) or procedures (e.g., hematopoietic stem cell transplantation) used 
in the protocol treatment.  If this study involves no other modalities or 
procedures, this section should be marked “N/A”. 
 
 5.2  Definition of Dose-Limiting Toxicity 
 
Please provide explicit definitions of the type(s), grade(s), and duration(s) of adverse 
events that will be considered dose-limiting toxicity(ies), or provide definitions of 
other endpoints that will be used to determine dose escalations. 
 
Management and dose modifications associated with the above adverse events are 
outlined in Section 6. 
 
Dose escalation will proceed within each cohort according to the following scheme.  
Dose-limiting toxicity (DLT) is defined above.  An accelerated titration design of the 
investigator's choice may be substituted.  An example can be found on the following 
Web site (http://linus.nci.nih.gov/~brb/Methodologic.htm).   
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Number of Patients with DLT 
at a Given Dose Level 
Escalation Decision Rule 
0 out of 3 Enter 3 patients at the next dose level. 
>2 Dose escalation will be stopped.  This dose level 
will be declared the maximally administered 
dose (highest dose administered).  Three (3) 
additional patients will be entered at the next 
lowest dose level if only 3 patients were treated 
previously at that dose. 
1 out of 3 Enter at least 3 more patients at this dose level. 
 If 0 of these 3 patients experience DLT, 
proceed to the next dose level. 
 If 1 or more of this group suffer DLT, then 
dose escalation is stopped, and this dose is 
declared the maximally administered dose.  
Three (3) additional patients will be entered 
at the next lowest dose level if only 3 
patients were treated previously at that dose. 
<1 out of 6 at highest dose level 
below the maximally 
administered dose 
This is generally the recommended phase 2 dose. 
At least 6 patients must be entered at the 
recommended phase 2 dose. 
 
 5.3  General Concomitant Medication and Supportive Care Guidelines 
 
Please state guidelines for use of concomitant medications or any additional 
appropriate supportive care medications or treatments.  The potential for interaction 
with the cytochrome P450 system should be addressed if applicable.  Please use or 
modify the following paragraph as appropriate. 
 
Because there is a potential for interaction of _CTEP IND Agent(s)_ with other 
concomitantly administered drugs through the cytochrome P450 system, the case 
report form must capture the concurrent use of all other drugs, over-the-counter 
medications, or alternative therapies.  The Principal Investigator should be alerted if 
the patient is taking any agent known to affect or with the potential to affect selected 
CYP450 isoenzymes. 
 
 5.4  Duration of Therapy 
 
In the absence of treatment delays due to adverse events, treatment may continue for      
(# cycles)    or until one of the following criteria applies: 
 
 Disease progression, 
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 Intercurrent illness that prevents further administration of treatment, 
 
 Unacceptable adverse event(s), 
 
 Patient decides to withdraw from the study, or 
 
 General or specific changes in the patient's condition render the patient 
unacceptable for further treatment in the judgment of the investigator. 
 
 5.5  Duration of Follow Up 
 
Patients will be followed for __weeks__ after removal from study or until death, 
whichever occurs first.  Patients removed from study for unacceptable adverse events 
will be followed until resolution or stabilization of the adverse event. 
 
 5.6  Criteria for Removal from Study 
 
Patients will be removed from study when any of the criteria listed in Section 5.3 
applies.  The reason for study removal and the date the patient was removed must be 
documented in the Case Report Form. 
 
 
6. DOSING DELAYS/DOSE MODIFICATIONS 
 
Treatment plans should explicitly identify when treatment (typically dose) modifications 
are appropriate.  Treatment modifications/dosing delays and the factors predicating 
treatment modification should be explicit and clear.  If dose modifications or treatment 
delays are anticipated, please provide a dose de-escalation schema. 
 
The following format for an orally available agent is provided as an example and should 
be modified as appropriate for this protocol: 
 
Dose Level Agent Name Dose 
-2 XX mg, schedule 
-1 XX mg, schedule 
+1 XX mg, schedule 
+2 XX mg, schedule 
+3 XX mg, schedule 
 
Note:  All treatment modifications must be expressed as a specific dose or amount rather 
than as a percentage of the starting or previous dose. 
Dose modifications/treatment delays for _CTEP IND Agent(s)_ and _Other Agent(s)_ 
may be presented separately or together, as appropriate.  Use of a table format is 
recommended if applicable. 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
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Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of AEs (Section 7.1) and the characteristics of an observed AE (Section 
7.2) will determine whether the event requires expedited (via AdEERS) in addition to 
routine reporting.   
 
 7.1  Comprehensive Adverse Events and Potential Risks Lists (CAEPRs) 
 
Sections provided below should be used or deleted as necessary. 
 
  7.1.1 CAEPRs for CTEP-Supplied Investigational Agent(s) 
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a 
single, complete list of reported and/or potential adverse events (AE) associated 
with an agent using a uniform presentation of events by body system.  In addition 
to the comprehensive list, a subset, the Agent Specific Adverse Event List 
(ASAEL), appears in a separate column and is identified with bold and italicized 
text.  This subset of AEs (the ASAEL) contains events that are considered 
„expected‟ for expedited reporting purposes only.  Refer to the “CTEP, NCI 
Guidelines: Adverse Event Reporting Requirements” 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adeers.htm) 
for further clarification.  The CAEPR may not provide frequency data; if not, 
refer to the Investigator‟s Brochure for this information. 
 
   7.1.1.1 CAEPR for _(CTEP IND Agent #1)_ 
 
The Comprehensive Adverse Events and Potential Risks (CAEPR) list will 
be provided with the LOI approval letter.  Please insert the CAEPR here. 
 
   7.1.1.2 CAEPR for _(CTEP IND Agent #2)_ 
 
The Comprehensive Adverse Events and Potential Risks (CAEPR) list will 
be provided with the LOI approval letter.  Please insert the CAEPR here. 
 
  7.1.2 Adverse Event List(s) for _[Other Investigational Agent(s)]_ 
 
Agent not supplied by CTEP:  Please include a comprehensive list of all reported 
adverse events and any potential risks (such as the toxicities seen with another 
agent of the same class or risks seen in animals administered this agent) as 
provided by the manufacturer. 
 
  7.1.3 Adverse Event List(s) for Commercial Agent(s) 
 
For each commercial agent, please provide a list of those adverse events most 
likely to occur on this study, and refer the reader to the package insert(s) for the 
comprehensive list of adverse events. 
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 7.2  Adverse Event Characteristics  
 
 CTCAE term (AE description) and grade:  The descriptions and grading scales 
found in the revised NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 will be utilized for AE reporting.  All appropriate 
treatment areas should have access to a copy of the CTCAE version 4.0.  A copy 
of the CTCAE version 4.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.   
 
 „Expectedness‟: AEs can be „Unexpected‟ or „Expected‟ (see Section 7.1 above) 
for expedited reporting purposes only.  „Expected‟ AEs (the ASAEL) are bold 
and italicized in the CAEPR (Section 7.1.1). 
 
 Attribution of the AE: 
 Definite – The AE is clearly related to the study treatment. 
 Probable – The AE is likely related to the study treatment. 
 Possible – The AE may be related to the study treatment. 
 Unlikely – The AE is doubtfully related to the study treatment. 
 Unrelated – The AE is clearly NOT related to the study treatment. 
 
 7.3  Expedited Adverse Event Reporting 
 
7.3.1 Expedited AE reporting for this study must use AdEERS (Adverse Event 
Expedited Reporting System), accessed via the CTEP home page 
(http://ctep.cancer.gov).  The reporting procedures to be followed are presented in 
the “CTEP, NCI Guidelines: Adverse Event Reporting Requirements” which can 
be downloaded from the CTEP home page (http://ctep.cancer.gov).  These 
requirements are briefly outlined in the table below (Section 7.3.3). 
 
In the rare occurrence when Internet connectivity is lost, an AE report may be 
submitted using CTEP's Adverse Event Expedited Report-Single Agent or 
Multiple Agent paper template (available at http://ctep.cancer.gov) and faxed to 
301-230-0159.  A 24-hour notification is to be made to CTEP by telephone at 
301-897-7497, only when Internet connectivity is disrupted.  Once Internet 
connectivity is restored, an AE report submitted on a paper template or a 24-hour 
notification phoned in must be entered electronically into AdEERS by the original 
submitter at the site. 
 
7.3.2 The following text is required for multi-institutional studies only and may be 
deleted for single institution studies. 
 
AdEERS is programmed for automatic electronic distribution of reports to the 
following individuals:  Study Coordinator of the Lead Organization, Principal 
Investigator, and the local treating physician.  AdEERS provides a copy feature 
for other e-mail recipients.  
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7.3.3 Expedited Reporting Guidelines– AdEERS Reporting Requirements for 
Adverse Events That Occur Within 30 Days
1
 of the Last Dose of the 
Investigational Agent on Phase 1 Trials 
 
Phase 1 Trials 
 
Grade 1 Grade 2 Grade 2 Grade 3 Grade 3 
Grades 
4 & 5
2 
Unexpected 
and 
Expected 
Unex-
pected 
Expected 
Unexpected Expected 
Unexpected
and 
Expected 
with 
Hospitali-
zation 
without 
Hospitali- 
zation 
with 
Hospitali- 
zation 
without 
Hospitali- 
zation 
Unrelated 
Unlikely 
Not 
Required 
Not 
Required 
Not 
Required 
10 
Calendar 
Days 
Not 
Required 
10 
Calendar 
Days 
Not 
Required 
24-Hour; 
5 Calendar 
Days 
Possible 
Probable 
Definite 
Not 
Required 
10 
Calendar 
Days 
Not 
Required 
24-Hour; 
5 Calendar 
Days 
24-Hour; 
5 Calendar 
Days 
10 
Calendar 
Days 
Not 
Required 
24-Hour; 
5 Calendar 
Days 
1
Adverse events with attribution of possible, probable, or definite that occur greater than 30 days after 
the last dose of treatment with an agent under a CTEP IND require reporting as follows: 
AdEERS 24-hour notification followed by complete report within 5 calendar days for: 
Grade 3 unexpected events with hospitalization or prolongation of hospitalization 
Grade 4 unexpected events 
Grade 5 expected events and unexpected events 
 
2
Although an AdEERS 24-hour notification is not required for death clearly related to progressive disease, a full 
report is required as outlined in the table. 
December 15, 2004 
 
Note:  All deaths on study require both routine and expedited reporting 
regardless of causality.  Attribution to treatment or other cause must be 
provided. 
 
 Expedited AE reporting timelines defined: 
 “24 hours; 5 calendar days” – The investigator must initially report the 
AE via AdEERS within 24 hours of learning of the event followed by 
a complete AdEERS report within 5 calendar days of the initial 24-
hour report. 
 “10 calendar days” - A complete AdEERS report on the AE must be 
submitted within 10 calendar days of the investigator learning of the 
event.  
 
 Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates 
hospitalization (or prolongation of existing hospitalization) must be reported 
regardless of attribution and designation as expected or unexpected with the 
exception of any events identified as protocol-specific expedited adverse 
event reporting exclusions.   
 
Any event that results in persistent or significant disabilities/incapacities, congenital 
anomalies, or birth defects must be reported via AdEERS if the 
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 event occurs following treatment with an agent under a CTEP IND. 
 
 Use the NCI protocol number and the protocol-specific patient ID assigned 
during trial registration on all reports. 
 
  7.3.4 Protocol-Specific Expedited Adverse Event Reporting Exclusions 
 
For this protocol only, certain AEs/grades are exceptions to the Expedited 
Reporting Guidelines and do not require expedited reporting (i.e., AdEERS).  The 
following AEs must be reported through the routine reporting mechanism 
(Section 7.4): 
 
CTCAE 
Category 
Adverse Event Grade 
Hospitalization/ 
Prolongation of 
Hospitalization 
Attribution Comments 
      
      
      
      
      
 
 7.4  Routine Adverse Event Reporting 
 
All Adverse Events must be reported in routine study data submissions.  AEs 
reported through AdEERS must also be reported in routine study data 
submissions. 
 
 7.5  Secondary AML/MDS 
 
Investigators are required to report cases of secondary AML/MDS occurring on or 
following treatment on NCI-sponsored chemotherapy protocols using the NCI/CTEP 
Secondary AML/MDS Report Form.  This form can be downloaded from the CTEP 
Web site (http://ctep.cancer.gov).  Refer to the “CTEP, NCI Guidelines: Adverse 
Event Reporting Requirements” (available at http://ctep.cancer.gov) for additional 
information about secondary AML/MDS reporting.  
 
 
8. PHARMACEUTICAL INFORMATION 
 
A list of the adverse events and potential risks associated with the investigational or 
commercial agents administered in this study can be found in Section 7.1. 
 
 8.1  CTEP-Supplied Investigational Agent(s)  
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Confidential pharmaceutical information for investigational study agents supplied by 
CTEP will be provided as attachments to the approved Letter of Intent (LOI) 
response and should be inserted below as indicated. 
 
  8.1.1 CTEP IND Agent #1 (NSC #) 
 
Insert pharmaceutical information for CTEP IND Agent #1 here. 
 
Availability 
 
  CTEP IND Agent #1   is an investigational agent supplied to investigators by the 
Division of Cancer Treatment and Diagnosis (DCTD), NCI. 
 
If the study agent is provided by the NCI under a Collaborative Agreement with 
the agent manufacturer, the text below must be included in the protocol.  
Information on the study agent‟s Collaborative Agreement status will be provided 
in the approved LOI response letter.  
 
  CTEP IND Agent #1    is provided to the NCI under a Collaborative Agreement 
between the Pharmaceutical Collaborator and the DCTD, NCI (see Section 12.3). 
 
  8.1.2 CTEP IND Agent #2 (NSC #) 
 
Insert pharmaceutical information for CTEP IND Agent #2 here.  If only a single 
CTEP IND Agent will be used in the trial, this section should be marked “N/A” 
and the text below deleted. 
 
Availability 
 
  CTEP IND Agent #2   is an investigational agent supplied to investigators by the 
Division of Cancer Treatment and Diagnosis (DCTD), NCI. 
 
If the study agent is provided by the NCI under a Collaborative Agreement with 
the agent manufacturer, the text below must be included in the protocol.  
Information on the study agent‟s Collaborative Agreement status will be provided 
in the approved LOI response letter.  
 
  CTEP IND Agent #2    is provided to the NCI under a Collaborative Agreement 
between the Pharmaceutical Collaborator and the DCTD, NCI (see Section 12.3). 
 
  8.1.3 Agent Ordering 
 
NCI-supplied agents may be requested by the Principal Investigator (or their 
authorized designee) at each participating institution.  Pharmaceutical 
Management Branch (PMB) policy requires that agent be shipped directly to the 
institution where the patient is to be treated.  PMB does not permit the transfer of 
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agents between institutions (unless prior approval from PMB is obtained.)  The 
CTEP-assigned protocol number must be used for ordering all CTEP-supplied 
investigational agents.  The responsible investigator at each participating 
institution must be registered with CTEP, DCTD through an annual submission of 
FDA Form 1572 (Statement of Investigator), Curriculum Vitae, Supplemental 
Investigator Data Form (IDF), and Financial Disclosure Form (FDF).  If there are 
several participating investigators at one institution, CTEP-supplied 
investigational agents for the study should be ordered under the name of one lead 
investigator at that institution. 
 
Agent may be requested by completing a Clinical Drug Request (NIH-986) and 
faxing it to the Pharmaceutical Management Branch at (301) 480-4612.  For 
questions about drug orders, transfers, returns, or accountability call (301) 496-
5725 Monday through Friday between 8:30 am and 4:30 pm (ET) or email 
PMBAfterHours@mail.nih.gov anytime. 
 
  8.1.4 Agent Accountability 
 
Agent Inventory Records – The investigator, or a responsible party designated by 
the investigator, must maintain a careful record of the inventory and disposition of 
all agents received from DCTD using the NCI Drug Accountability Record Form 
(DARF).  (See the CTEP home page at http://ctep.cancer.gov for the Procedures 
for Drug Accountability and Storage and to obtain a copy of the DARF and 
Clinical Drug Request form.) 
 
 8.2  Other Investigational Agent(s) 
 
If there are no other investigational agent(s) in this study, this section should be 
marked “N/A” and the instructions below deleted. 
 
A separate pharmaceutical section is needed for each investigational agent 
containing at least the following information, available from the appropriate 
investigator‟s brochure: 
 
Product description:  Include the available dosage forms, ingredients, and 
packaging, as appropriate.  Also state the agent's supplier.   
 
Solution preparation (how the dose is to be prepared):  Include reconstitution 
directions and directions for further dilution, if appropriate. 
 
Storage requirements:  Include the requirements for the original dosage form, 
reconstituted solution, and final diluted product, as applicable. 
 
Stability:  Include the stability of the original dosage form, reconstituted solution, 
and final diluted product, as applicable. 
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Route of administration:  Include a description of the method to be used and the rate 
of administration, if applicable.  For example, continuous intravenous infusion over 
24 hours, short intravenous infusion over 30-60 minutes, intravenous bolus, etc.  
Describe any precautions required for safe administration. 
 
 8.3  Commercial Agent(s) 
 
If there are no commercial agent(s) in this study, this section should be marked 
“N/A” and the instructions below deleted. 
 
A separate pharmaceutical section is needed for each agent containing at least the 
following information, available in the manufacturer's current package insert: 
 
Product description:  Include any dosage form(s), ingredients, and packaging 
applicable to the protocol.  Also, state the agent's supplier or state that it is 
commercially available. 
 
Solution preparation (how the dose is to be prepared):  Investigators may refer the 
reader to the package insert for 'standard' preparation instructions.  If the agent is to 
be prepared in a 'non-standard' or protocol-specific fashion, the reconstitution 
directions and instructions for further dilution must be included.  Appropriate storage 
and stability information should be included to support the method of preparation. 
 
Route of administration:  Include a description of the method to be used and the rate 
of administration, if applicable.  For example, continuous intravenous infusion over 
24 hours, short intravenous infusion over 30-60 minutes, intravenous bolus, etc.  
Describe any precautions required for safe administration. 
 
 
9. CORRELATIVE/SPECIAL STUDIES 
 
Please briefly describe all planned correlative studies with reference to the “Guidelines for 
Correlative Studies in Clinical Trials” provided with the LOI response and available on the 
CTEP Web site (http://ctep.cancer.gov/protocolDevelopment/default.htm).  Explicit 
instructions for handling, preserving, and shipping the specimens should be provided 
below.  Information on endpoint validation including additional background (as needed), 
description of the assay(s) used, materials and methods, and assay validation should be 
provided in an appendix.  A plan for statistical analysis of the results of the correlative 
study(ies) should be provided in Section 13.4, Analysis of Secondary Endpoints. 
 
If development of diagnostic assays to identify patients who might benefit from a molecularly 
targeted therapy is planned, validation in a central reference laboratory, tissue banking, and 
standardization of procedures is of high importance.  If samples will be shipped to a central 
laboratory for processing and analysis, responsible parties and contact information should 
be provided below in addition to instructions for handling, preserving, and shipping the 
specimens. 
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A correlative study title using meaningful descriptive text should be provided for each 
planned correlative study using the Protocol Submission Worksheet found on the CTEP Web 
site (http://ctep.cancer.gov/protocolDevelopment/default.htm).  These titles will facilitate 
documentation of contributions to basic science in the context of the clinical trial. 
 
A suggested format for presentation of the required information is shown below and may be 
used or modified as required.  If this trial does not include correlative or special studies, this 
section should be marked “N/A” and all instructions as well as the text below deleted. 
 
 9.1  Laboratory Correlative Studies 
 
  9.1.1 (Title – Laboratory Correlative Study #1) 
   9.1.1.1 Collection of Specimen(s) 
   9.1.1.2 Handling of Specimens(s) 
   9.1.1.3 Shipping of Specimen(s) 
   9.1.1.4 Site(s) Performing Correlative Study 
 
  9.1.2 (Title – Laboratory Correlative Study #2) 
   9.1.2.1 Collection of Specimen(s) 
   9.1.2.2 Handling of Specimens(s) 
   9.1.2.3 Shipping of Specimen(s) 
   9.1.2.4 Site(s) Performing Correlative Study   
 
 9.2  Special Studies 
 
  9.2.1 (Title – Special Correlative Study #1) 
   9.2.1.1 Outcome Measure 
   9.2.1.2 Assessment 
    9.2.1.2.1 Method of Assessment 
    9.2.1.2.2 Timing of Assessment 
   9.2.1.3 Data Recording 
    9.2.1.3.1 Method of Recording 
    9.2.1.3.2 Timing of Recording 
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10. STUDY CALENDAR 
 
Schedules shown in the Study Calendar below are provided as an example and should be 
modified as appropriate. 
 
Baseline evaluations are to be conducted within 1 week prior to start of protocol therapy.  
Scans and x-rays must be done <4 weeks prior to the start of therapy.  In the event that the 
patient‟s condition is deteriorating, laboratory evaluations should be repeated within 48 hours 
prior to initiation of the next cycle of therapy. 
 
 
Pre- 
Study 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
4 
Wk 
5 
Wk 
6 
Wk 
7 
Wk 
8 
Wk 
9 
Wk 
10 
Wk 
11 
Wk 
12 
Off Study
c
 
CTEP IND Agent  A   A   A   A    
Other Agent(s)  B B  B B  B B  B B   
Informed consent X              
Demographics X              
Medical history X              
Concurrent meds X X---------------------------------------------------------------------------------------------X  
Physical exam X X   X   X   X   X 
Vital signs X X   X   X   X   X 
Height X              
Weight X X   X   X   X   X 
Performance status X X   X   X   X   X 
CBC w/diff, plts X X X X X X X X X X X X X X 
Serum chemistry
a
 X X X X X X X X X X X X X X 
EKG (as indicated) X              
Adverse event evaluation  X---------------------------------------------------------------------------------------------X X 
Tumor measurements 
X 
Tumor measurements are repeated every   [#  weeks]   weeks.  
Documentation (radiologic) must be provided for patients removed from 
study for progressive disease. 
X
c
 
Radiologic evaluation X Radiologic measurements should be performed every   [#  weeks]   weeks. X
c
 
B-HCG X
b
              
Other tests, as appropriate               
Other correlative studies               
A: CTEP IND Agent:  Dose as assigned; administration schedule 
B: Other Agent(s):  Dose as assigned; administration schedule 
a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, 
phosphorus, potassium, total protein, SGOT [AST], SGPT [ALT], sodium. 
b: Serum pregnancy test (women of childbearing potential). 
c: Off-study evaluation.   
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11. MEASUREMENT OF EFFECT 
 
Please provide response criteria.  If the criteria for solid tumors below are not applicable, 
the investigator(s) should provide agent- or disease-appropriate criteria (e.g., for specific 
hematologic malignancies, supportive care agents, etc.) with references, and all solid tumor 
criteria should be deleted.  
 
Although response is not the primary endpoint of this trial, patients with measurable disease 
will be assessed by standard criteria.  For the purposes of this study, patients should be re-
evaluated every    # of weeks   weeks.  In addition to a baseline scan, confirmatory scans will 
also be obtained    # of weeks   weeks following initial documentation of an objective 
response. 
 
 11.1 Antitumor Effect – Solid Tumors 
 
For the purposes of this study, patients should be re-evaluated for response every   [# 
of weeks]   weeks.  In addition to a baseline scan, confirmatory scans should also be 
obtained   [# of weeks] (not less than 4) weeks following initial documentation of 
objective response. 
 
Response and progression will be evaluated in this study using the new international 
criteria proposed by the revised Response Evaluation Criteria in Solid Tumors 
(RECIST) guideline (version 1.1) [Eur J Ca 45:228-247, 2009].  Changes in the 
largest diameter (unidimensional measurement) of the tumor lesions and the shortest 
diameter in the case of malignant lymph nodes are used in the RECIST criteria. 
 
  11.1.1 Definitions 
 
Evaluable for toxicity.  All patients will be evaluable for toxicity from the time of 
their first treatment with _[Agent Name]_. 
 
Evaluable for objective response.  Only those patients who have measurable 
disease present at baseline, have received at least one cycle of therapy, and have 
had their disease re-evaluated will be considered evaluable for response.  These 
patients will have their response classified according to the definitions stated 
below.  (Note:  Patients who exhibit objective disease progression prior to the end 
of cycle 1 will also be considered evaluable.) 
 
Evaluable Non-Target Disease Response.  Patients who have lesions present at 
baseline that are evaluable but do not meet the definitions of measurable disease, 
have received at least one cycle of therapy, and have had their disease re-
evaluated will be considered evaluable for non-target disease.  The response 
assessment is based on the presence, absence, or unequivocal progression of the 
lesions.  
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  11.1.2 Disease Parameters 
 
Measurable disease.  Measurable lesions are defined as those that can be 
accurately measured in at least one dimension (longest diameter to be recorded) as 
>20 mm by chest x-ray, as >10 mm with CT scan, or >10 mm with calipers by 
clinical exam.  All tumor measurements must be recorded in millimeters (or 
decimal fractions of centimeters). 
 
Note:  Tumor lesions that are situated in a previously irradiated area might or 
might not be considered measurable.  If the investigator thinks it appropriate to 
include them, the conditions under which such lesions should be considered must 
be defined in the protocol. 
 
Malignant lymph nodes.  To be considered pathologically enlarged and 
measurable, a lymph node must be >15 mm in short axis when assessed by CT 
scan (CT scan slice thickness recommended to be no greater than 5 mm).  At 
baseline and in follow-up, only the short axis will be measured and followed. 
 
Non-measurable disease.  All other lesions (or sites of disease), including small 
lesions (longest diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 
mm short axis), are considered non-measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis 
cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not 
followed by CT or MRI), are considered as non-measurable. 
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple 
cysts should not be considered as malignant lesions (neither measurable nor non-
measurable) since they are, by definition, simple cysts. 
 
„Cystic lesions‟ thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. 
However, if non-cystic lesions are present in the same patient, these are preferred 
for selection as target lesions. 
 
Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ 
and 5 lesions in total, representative of all involved organs, should be identified as 
target lesions and recorded and measured at baseline.  Target lesions should be 
selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend 
themselves to reproducible repeated measurements.  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in 
which circumstance the next largest lesion which can be measured reproducibly 
should be selected.  A sum of the diameters (longest for non-nodal lesions, short 
axis for nodal lesions) for all target lesions will be calculated and reported as the 
baseline sum diameters.  If lymph nodes are to be included in the sum, then only 
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the short axis is added into the sum.  The baseline sum diameters will be used as 
reference to further characterize any objective tumor regression in the measurable 
dimension of the disease. 
 
Non-target lesions.  All other lesions (or sites of disease) including any 
measurable lesions over and above the 5 target lesions should be identified as 
non-target lesions and should also be recorded at baseline.  Measurements of 
these lesions are not required, but the presence, absence, or in rare cases 
unequivocal progression of each should be noted throughout follow-up.  
 
  11.1.3 Methods for Evaluation of Measurable Disease 
 
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to 
the beginning of treatment and never more than 4 weeks before the beginning of 
the treatment. 
 
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during follow-up. 
Imaging-based evaluation is preferred to evaluation by clinical examination 
unless the lesion(s) being followed cannot be imaged but are assessable by 
clinical exam. 
 
Clinical lesions  Clinical lesions will only be considered measurable when they 
are superficial (e.g., skin nodules and palpable lymph nodes) and 10 mm 
diameter as assessed using calipers (e.g., skin nodules).  In the case of skin 
lesions, documentation by color photography, including a ruler to estimate the 
size of the lesion, is recommended.  
 
Chest x-ray  Lesions on chest x-ray are acceptable as measurable lesions when 
they are clearly defined and surrounded by aerated lung.  However, CT is 
preferable.  
 
Conventional CT and MRI  This guideline has defined measurability of lesions on 
CT scan based on the assumption that CT slice thickness is 5 mm or less.  If CT 
scans have slice thickness greater than 5 mm, the minimum size for a measurable 
lesion should be twice the slice thickness.  MRI is also acceptable in certain 
situations (e.g. for body scans).   
 
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and 
temporal resolution; however, there are many image acquisition variables 
involved in MRI, which greatly impact image quality, lesion conspicuity, and 
measurement.  Furthermore, the availability of MRI is variable globally.  As with 
CT, if an MRI is performed, the technical specifications of the scanning 
sequences used should be optimized for the evaluation of the type and site of 
disease.  Furthermore, as with CT, the modality used at follow-up should be the 
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same as was used at baseline and the lesions should be measured/assessed on the 
same pulse sequence.  It is beyond the scope of the RECIST guidelines to 
prescribe specific MRI pulse sequence parameters for all scanners, body parts, 
and diseases.  Ideally, the same type of scanner should be used and the image 
acquisition protocol should be followed as closely as possible to prior scans.  
Body scans should be performed with breath-hold scanning techniques, if 
possible. 
 
PET-CT  At present, the low dose or attenuation correction CT portion of a 
combined PET-CT is not always of optimal diagnostic CT quality for use with 
RECIST measurements.  However, if the site can document that the CT 
performed as part of a PET-CT is of identical diagnostic quality to a diagnostic 
CT (with IV and oral contrast), then the CT portion of the PET-CT can be used 
for RECIST measurements and can be used interchangeably with conventional 
CT in accurately measuring cancer lesions over time.  Note, however, that the 
PET portion of the CT introduces additional data which may bias an investigator 
if it is not routinely or serially performed.   
 
Ultrasound  Ultrasound is not useful in assessment of lesion size and should not 
be used as a method of measurement.  Ultrasound examinations cannot be 
reproduced in their entirety for independent review at a later date and, because 
they are operator dependent, it cannot be guaranteed that the same technique and 
measurements will be taken from one assessment to the next.  If new lesions are 
identified by ultrasound in the course of the study, confirmation by CT or MRI is 
advised.  If there is concern about radiation exposure at CT, MRI may be used 
instead of CT in selected instances. 
 
Endoscopy, Laparoscopy  The utilization of these techniques for objective tumor 
evaluation is not advised.  However, such techniques may be useful to confirm 
complete pathological response when biopsies are obtained or to determine 
relapse in trials where recurrence following complete response (CR) or surgical 
resection is an endpoint. 
 
Tumor markers  Tumor markers alone cannot be used to assess response.  If 
markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response.  Specific guidelines for 
both CA-125 response (in recurrent ovarian cancer) and PSA response (in 
recurrent prostate cancer) have been published [JNCI 96:487-488, 2004; J Clin 
Oncol 17, 3461-3467, 1999; J Clin Oncol 26:1148-1159, 2008].  In addition, the 
Gynecologic Cancer Intergroup has developed CA-125 progression criteria which 
are to be integrated with objective tumor assessment for use in first-line trials in 
ovarian cancer [JNCI 92:1534-1535, 2000]. 
 
Cytology, Histology  These techniques can be used to differentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in 
tumor types, such as germ cell tumors, where known residual benign 
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tumors can remain). 
The cytological confirmation of the neoplastic origin of any effusion that appears 
or worsens during treatment when the measurable tumor has met criteria for 
response or stable disease is mandatory to differentiate between response or stable 
disease (an effusion may be a side effect of the treatment) and progressive 
disease. 
 
FDG-PET  While FDG-PET response assessments need additional study, it is 
sometimes reasonable to incorporate the use of FDG-PET scanning to 
complement CT scanning in assessment of progression (particularly possible 'new' 
disease).  New lesions on the basis of FDG-PET imaging can be identified 
according to the following algorithm:  
a) Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a 
sign of PD based on a new lesion. 
b) No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the 
positive FDG-PET at follow-up corresponds to a new site of disease 
confirmed by CT, this is PD.  If the positive FDG-PET at follow-up is not 
confirmed as a new site of disease on CT, additional follow-up CT  scans 
are needed to determine if there is truly progression occurring at that site 
(if so, the date of PD will be the date of the initial abnormal FDG-PET 
scan).  If the positive FDG-PET at follow-up corresponds to a pre-existing 
site of disease on CT that is not progressing on the basis of the anatomic 
images, this is not PD. 
c) FDG-PET may be used to upgrade a response to a CR in a manner similar 
to a biopsy in cases where a residual radiographic abnormality is thought 
to represent fibrosis or scarring.  The use of FDG-PET in this 
circumstance should be prospectively described in the protocol and 
supported by disease-specific medical literature for the indication.  
However, it must be acknowledged that both approaches may lead to false 
positive CR due to limitations of FDG-PET and biopsy 
resolution/sensitivity. 
  
Note:  A „positive‟ FDG-PET scan lesion means one which is FDG avid with an 
uptake greater than twice that of the surrounding tissue on the attenuation 
corrected image. 
 
  11.1.4 Response Criteria 
 
   11.1.4.1 Evaluation of Target Lesions 
 
Complete Response (CR): Disappearance of all target lesions.  Any 
pathological lymph nodes (whether target or 
non-target) must have reduction in short axis 
to <10 mm. 
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Partial Response (PR): At least a 30% decrease in the sum of the 
diameters of target lesions, taking as 
reference the baseline sum diameters. 
 
Progressive Disease (PD): At least a 20% increase in the sum of the 
diameters of target lesions, taking as 
reference the smallest sum on study (this 
includes the baseline sum if that is the 
smallest on study).  In addition to the 
relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 
5 mm.  (Note:  the appearance of one or 
more new lesions is also considered 
progressions). 
 
Stable Disease (SD): Neither sufficient shrinkage to qualify for 
PR nor sufficient increase to qualify for PD, 
taking as reference the smallest sum 
diameters while on study. 
 
   11.1.4.2 Evaluation of Non-Target Lesions 
 
Complete Response (CR): Disappearance of all non-target lesions and 
normalization of tumor marker level.  All 
lymph nodes must be non-pathological in 
size (<10 mm short axis). 
 
Note:  If tumor markers are initially above 
the upper normal limit, they must normalize 
for a patient to be considered in complete 
clinical response. 
 
Non-CR/Non-PD: Persistence of one or more non-target 
lesion(s) and/or maintenance of tumor 
marker level above the normal limits. 
 
Progressive Disease (PD): Appearance of one or more new lesions 
and/or unequivocal progression of existing 
non-target lesions.  Unequivocal 
progression should not normally trump 
target lesion status.  It must be 
representative of overall disease status 
change, not a single lesion increase.     
 
Although a clear progression of “non-target” lesions only is exceptional, 
the opinion of the treating physician should prevail in such circumstances, 
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and the progression status should be confirmed at a later time by the 
review panel (or Principal Investigator). 
   11.1.4.3 Evaluation of Best Overall Response 
 
The best overall response is the best response recorded from the start of 
the treatment until disease progression/recurrence (taking as reference for 
progressive disease the smallest measurements recorded since the 
treatment started).  The patient's best response assignment will depend on 
the achievement of both measurement and confirmation criteria. 
    
For Patients with Measurable Disease (i.e., Target Disease) 
Target 
Lesions 
Non-
Target 
Lesions 
New 
Lesions 
Overall 
Response 
Best Overall 
Response when 
Confirmation is 
Required* 
CR CR No CR 
>4 wks. 
Confirmation** 
CR 
Non-
CR/Non-
PD 
No PR 
>4 wks. 
Confirmation** 
CR 
Not 
evaluated 
No PR 
PR 
Non-
CR/Non-
PD/not 
evaluated 
No PR 
SD 
Non-
CR/Non-
PD/not 
evaluated 
No SD 
documented at least 
once >4 wks. from 
baseline** 
PD Any 
Yes or 
No 
PD 
no prior SD, PR or CR 
Any PD*** 
Yes or 
No 
PD 
Any Any Yes PD 
*  See RECIST 1.1 manuscript for further details on what is evidence 
of a new lesion. 
**  Only for non-randomized trials with response as primary endpoint. 
*** In exceptional circumstances, unequivocal progression in non-
target lesions may be accepted as disease progression. 
 
Note: Patients with a global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease 
progression at that time should be reported as “symptomatic 
deterioration.”  Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
95 
 
 
For Patients with Non-Measurable Disease (i.e., Non-Target Disease) 
Non-Target Lesions New Lesions Overall Response 
CR No CR 
Non-CR/non-PD No Non-CR/non-PD* 
Not all evaluated No not evaluated 
Unequivocal PD Yes or No PD 
Any Yes PD 
* „Non-CR/non-PD‟ is preferred over „stable disease‟ for non-target disease 
since SD is increasingly used as an endpoint for assessment of efficacy in 
some trials so to assign this category when no lesions can be measured is not 
advised 
 
  11.1.5 Duration of Response 
 
Duration of overall response:  The duration of overall response is measured from 
the time measurement criteria are met for CR or PR (whichever is first recorded) 
until the first date that recurrent or progressive disease is objectively documented 
(taking as reference for progressive disease the smallest measurements recorded 
since the treatment started). 
 
The duration of overall CR is measured from the time measurement criteria are 
first met for CR until the first date that progressive disease is objectively 
documented.  
 
Duration of stable disease:  Stable disease is measured from the start of the 
treatment until the criteria for progression are met, taking as reference the 
smallest measurements recorded since the treatment started, including the baseline 
measurements.  
 
  11.1.6 Progression-Free Survival 
 
Include this section if time to progression or progression-free survival (PFS) is to 
be used.  PFS is defined as the duration of time from start of treatment to time of 
progression or death, whichever occurs first. 
 
  11.1.7 Response Review 
 
For trials where the response rate is the primary endpoint, it is strongly 
recommended that all responses be reviewed by an expert(s) independent of the 
study at the study‟s completion.  Simultaneous review of the patients‟ files and 
radiological images is the best approach.  
 
 
 
 11.2 Antitumor Effect – Hematologic Tumors 
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Please provide appropriate criteria for evaluation of response and methods of 
measurement. 
 
 11.3 Other Response Parameters 
 
Other endpoints and the criteria for their measurement should be entered below or 
reference should be made to the protocol section where these criteria may be found. 
 
 
12. DATA REPORTING / REGULATORY REQUIREMENTS 
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 
(Adverse Events: List and Reporting Requirements). 
 
 12.1 Data Reporting 
 
  12.1.1 Method 
 
Please use the appropriate text below, if known. 
 
This study will be monitored by the Clinical Trials Monitoring Service (CTMS).  
Information on CTMS reporting is available at 
http://www.theradex.com/CTMS/ctmsmenu.htm.  Data will be submitted to 
CTMS at least once every two weeks on the NCI/DCTD case report form or the 
electronic case report form (ACES). 
 
OR 
 
This study will be monitored by the Clinical Data Update System (CDUS) version 
3.0.  Cumulative CDUS data will be submitted quarterly to CTEP by electronic 
means.  Reports are due January 31, April 30, July 31 and October 31.  
Instructions for submitting data using the CDUS can be found on the CTEP Web 
site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/cdus.htm). 
 
Note:  All adverse events that have occurred on the study, including those 
reported through AdEERS, must be reported via the monitoring method identified 
above. 
 
  12.1.2. Responsibility for Data Submission 
 
Suggested text is provided below which can be modified as necessary.  If this 
study is being performed within a single institution, this section should be marked 
“N/A” and the text below deleted. 
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Study participants are responsible for submitting CDUS data and/or data forms to 
the Coordinating Center quarterly by _(date for Q1 data)_, _(date for Q2 data)_, 
_(date for Q3 data)_, and _(date for Q4 data)_ to allow time for Coordinating 
Center compilation, Principal Investigator review, and timely submission to 
CTEP (see Section 12.1.1.).  For trials monitored by CTMS, a quarterly report of 
data will be provided by Theradex to the Coordinating Center. 
 
The Coordinating Center is responsible for compiling and submitting CDUS data 
to CTEP for all participants and for providing the data to the Principal 
Investigator for review.   
 
 12.2 CTEP Multicenter Guidelines 
 
Suggested text is provided below which can be modified as necessary.  If this study is 
being performed within a single institution, this section should be marked “N/A” and 
the text below deleted. 
 
This protocol will adhere to the policies and requirements of the CTEP Multicenter 
Guidelines.  The specific responsibilities of the Principal Investigator and the 
Coordinating Center (Study Coordinator) and the procedures for auditing are 
presented in Appendix B. 
 
 The Principal Investigator/Coordinating Center is responsible for distributing all 
IND Action Letters or Safety Reports received from CTEP to all participating 
institutions for submission to their individual IRBs for action as required. 
 
 Except in very unusual circumstances, each participating institution will order 
DCTD-supplied agents directly from CTEP.  Agents may be ordered by a 
participating site only after the initial IRB approval for the site has been 
forwarded by the Coordinating Center to the CTEP PIO (PIO@ctep.nci.nih.gov) 
except for Group studies. 
 
 12.3 Collaborative Agreements Language 
 
If the investigational study agent is provided by CTEP under a Collaborative 
Agreement [Cooperative Research and Development Agreement (CRADA), Clinical 
Trials Agreement (CTA), Agent-CRADA or Clinical Supply Agreement (CSA)] with 
the Pharmaceutical Company, this section must be included in the protocol.  
Information on the investigational study agent‟s Agreement status will be provided in 
the approved LOI response.  If no Collaborative Agreement  applies to the 
investigational study agent, this section should be marked “N/A” and the text below 
deleted.  
 
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to 
the NCI under a Collaborative Agreement (CRADA, Agent-CRADA, CTA, CSA) 
between the Pharmaceutical Company(ies) (hereinafter referred to as 
98 
 
“Collaborator(s)”) and the NCI Division of Cancer Treatment and Diagnosis.  
Therefore, the following obligations/guidelines, in addition to the provisions in the 
“Intellectual Property Option to Collaborator” (http:// ctep.cancer.gov/industry) 
contained within the terms of award, apply to the use of the Agent(s) in this study: 
 
1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor 
can Agent(s) be transferred or licensed to any party not participating in the 
clinical study.  Collaborator(s) data for Agent(s) are confidential and proprietary 
to Collaborator(s) and shall be maintained as such by the investigators.  The 
protocol documents for studies utilizing investigational Agents contain 
confidential information and should not be shared or distributed without the 
permission of the NCI.  If a copy of this protocol is requested by a patient or 
patient‟s family member participating on the study, the individual should sign a 
confidentiality agreement.  A suitable model agreement can be downloaded from: 
http://ctep.cancer.gov. 
 
2. For a clinical protocol where there is an investigational Agent used in 
combination with (an)other investigational Agent(s), each the subject of different 
collaborative agreements , the access to and use of data by each Collaborator shall 
be as follows (data pertaining to such combination use shall hereinafter be 
referred to as “Multi-Party Data”. ): 
 
a. NCI will provide all Collaborators with prior written notice regarding the 
existence and nature of any agreements governing their collaboration with 
NIH, the design of the proposed combination protocol, and the existence of 
any obligations that would tend to restrict NCI's participation in the proposed 
combination protocol. 
 
b. Each Collaborator shall agree to permit use of the Multi-Party Data from the 
clinical trial by any other Collaborator solely to the extent necessary to allow 
said other Collaborator to develop, obtain regulatory approval or 
commercialize its own investigational Agent. 
 
c. Any Collaborator having the right to use the Multi-Party Data from these trials 
must agree in writing prior to the commencement of the trials that it will use 
the Multi-Party Data solely for development, regulatory approval, and 
commercialization of its own investigational Agent. 
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative 
Agreement will be made available exclusively to Collaborator(s), the NCI, and 
the FDA, as appropriate and unless additional disclosure is required by law or 
court order.  Additionally, all Clinical Data and Results and Raw Data will be 
collected, used, and disclosed consistent with all applicable federal statutes and 
regulations for the protection of human subjects including, if applicable, the 
Standards for Privacy of Individually Identifiable Health Information set forth in 
45 CFR Part 164. 
99 
 
 
4. When a Collaborator wishes to initiate a data request, the request should first be 
sent to the NCI, who will then notify the appropriate investigators (Group Chair 
for Cooperative Group studies, or PI for other studies) of Collaborator's wish to 
contact them. 
 
5. Any data provided to Collaborator(s) for Phase 3 studies must be in accordance 
with the guidelines and policies of the responsible Data Monitoring Committee 
(DMC), if there is a DMC for this clinical trial. 
 
6. Any manuscripts reporting the results of this clinical trial must be provided to 
CTEP by the Group office for Cooperative Group studies or by the principal 
investigator for non-Cooperative Group studies for immediate delivery to 
Collaborator(s) for advisory review and comment prior to submission for 
publication.  Collaborator(s) will have 30 days from the date of receipt for review.  
Collaborator shall have the right to request that publication be delayed for up to 
an additional 30 days in order to ensure that Collaborator‟s confidential and 
proprietary data, in addition to Collaborator(s)‟s intellectual property rights, are 
protected.  Copies of abstracts must be provided to CTEP for forwarding to 
Collaborator(s) for courtesy review as soon as possible and preferably at least 
three (3) days prior to submission, but in any case, prior to presentation at the 
meeting or publication in the proceedings.  Press releases and other media 
presentations must also be forwarded to CTEP prior to release.  Copies of any 
manuscript, abstract and/or press release/ media presentation should be sent to: 
 
Regulatory Affairs Branch, CTEP, DCTD, NCI 
Executive Plaza North, Suite 7111 
Bethesda, Maryland  20892 
FAX 301-402-1584 
Email: ncicteppubs@mail.nih.gov  
 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No 
publication, manuscript or other form of public disclosure shall contain any of 
Collaborator‟s confidential/ proprietary information. 
 
 
13. STATISTICAL CONSIDERATIONS 
 
 13.1 Study Design/Endpoints 
 
Please specify the study design and primary endpoints.  Include information on how 
toxicity will be graded and reported, and state that all patients who receive any 
amount of the study drug will be evaluable for toxicity.  Precisely define the dose 
escalation scheme and MTD definition (or refer to the section where they are 
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defined).  Accelerated escalation designs with intrapatient dose escalation are 
encouraged.  An example can be found on the following Web site 
(http://linus.nci.nih.gov/~brb/Methodologic.htm).  If an optimal biologic dose will be 
determined in place of or in addition to the MTD, precisely define how this will be 
done. 
 
 13.2 Sample Size/Accrual Rate 
 
Please specify the planned sample size and accrual rate (e.g., patients/month). 
 
 13.3 Stratification Factors 
 
Please specify any planned patient stratification factors.  Indicate whether dose 
escalation and MTD determination will be done for each stratum individually.   
 
 13.4 Analysis of Secondary Endpoints 
 
If secondary endpoints are included in this study, please specify how they will be 
analyzed.  In particular, brief descriptions should be given of analyses of 
pharmacokinetic, biologic, and correlative laboratory endpoints. 
 
If responses are reported as a secondary endpoint, the following criteria should be 
used.  Every report should contain all patients included in the study.  For the 
response calculation, the report should contain at least a section with all eligible 
patients.  Another section of the report may detail the response rate for evaluable 
patients only.  However, a response rate analysis based on a subset of patients must 
explain which patients were excluded and for which reasons.  It is preferred that 95% 
confidence limits are given. 
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Informed Consent Template for Cancer Treatment Trials 
 
* NOTES FOR INFORMED CONSENT AUTHORS:  
 Model text suggested for use in the informed consent form is in bold.  It is recommended 
that the bold text be retained when adapting the template to a specific protocol. 
 Instructions and examples for informed consent authors are in [italics].  
 A blank line,  __________, indicates that the local investigator should provide the 
appropriate information before the document is reviewed with the prospective research 
participant.  
 The term „study doctor‟ has been used throughout the template because the Principal 
Investigator of a cancer treatment trial is a physician.   If this template is used for a trial 
where the Principal Investigator is not a physician, another appropriate term should be 
used instead of „study doctor‟.  
 The template date in the header is for reference to this template only and should not be 
included in the informed consent form given to the prospective research participant.  
 
* NOTES FOR LOCAL INVESTIGATORS:  
 The goal of the informed consent process is to provide people with sufficient information 
for making informed choices.   The informed consent form provides a summary of the 
clinical study and the individual's rights as a research participant.  It serves as a starting 
point for the necessary exchange of information between the investigator and potential 
research participant.  This template for the informed consent form is only one part of the 
larger process of informed consent.  For more information about informed consent, 
review the "Recommendations for the Development of Informed Consent Documents for 
Cancer Clinical Trials" prepared by the Comprehensive Working Group on Informed 
Consent in Cancer Clinical Trials for the National Cancer Institute.  The Web site address 
for this document is http://cancer.gov/clinicaltrials/understanding/simplification-of-
informed-consent-docs/. 
 A blank line,  __________, indicates that the local investigator should provide the 
appropriate information before the document is reviewed with the prospective research 
participant.  
 Suggestion for Local Investigators:  An NCI pamphlet explaining clinical trials is 
available for your patients.  The pamphlet is entitled:  "Taking Part in Cancer Treatment 
Research Studies".  This pamphlet may be ordered on the NCI Web site at 
https://cissecure.nci.nih.gov/ncipubs or call 1-800-4- CANCER (1-800-422-6237) to 
request a free copy.  
 Optional feature for Local Investigators:  Reference and attach drug sheets, 
pharmaceutical information for the public, or other material on risks.  Check with your 
local IRB regarding review of additional materials. 
 
* These notes for authors and investigators are instructional and should not be included 
in the informed consent form given to the prospective research participant.  
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Study Title 
 
This is a clinical trial, a type of research study.  Your study doctor will explain the clinical 
trial to you.  Clinical trials include only people who choose to take part.  Please take your 
time to make your decision about taking part.  You may discuss your decision with your 
friends and family.  You can also discuss it with your health care team.  If you have any 
questions, you can ask your study doctor for more explanation.  
 
You are being asked to take part in this study because you have [Type/stage/presentation of 
cancer being studied is briefly described here. For example: “Colon cancer that has spread and 
has not responded to one treatment”.]  
 
 
Why is this study being done? 
 
The purpose of this study is to….  [Limit explanation to why study is being done.  Include a 
brief explanation of the mechanism of action of the study agent in lay language and why an 
agent with this mechanism is being studied in this kind of cancer.  Explain in 1-3 sentences. 
Some examples are provided.]  
 
[Example: Phase 1 study] 
 
Test the safety of [drug/intervention] at different dose levels.  We want to find out what effects, 
good and/or bad, it has on you and your [specify type/stage/presentation of] cancer.   
 
[Complete and include the following sentence if appropriate.]  [Agent name] is an 
investigational or experimental anticancer agent that has not yet been approved by the 
Food and Drug Administration for use in this [type/stage/presentation of cancer]. 
 
 
How many people will take part in the study? 
 
About [state total accrual goal here] people will take part in this study.  [If appropriate, a 
short description about cohorts can be given here.  For example: “At the beginning of the study, 
(enter number of first cohort) patients will be treated with a low dose of the drug.  If this dose 
does not cause bad side effects, it will slowly be made higher as new patients take part in the 
study.  A total of (enter maximum number) patients are the most that would be able to enter the 
study”.  
 
 
What will happen if I take part in this research study?   
 
[List tests and procedures and their frequency under the categories below.  Include whether a 
patient will be at home, in the hospital, or in an outpatient setting.] 
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Before you begin the study …  
You will need to have the following exams, tests or procedures to find out if you can be in 
the study.  These exams, tests or procedures are part of regular cancer care and may be 
done even if you do not join the study.  If you have had some of them recently, they may not 
need to be repeated.  This will be up to your study doctor. 
 [List tests and procedures as appropriate.  Use bulleted format.] 
 
During the study …  
If the exams, tests and procedures show that you can be in the study, and you choose to 
take part, then you will need the following tests and procedures.  They are part of regular 
cancer care.  
 [List tests and procedures as appropriate.  Use bulleted format.] 
 
You will need these tests and procedures that are part of regular cancer care.   They are 
being done more often because you are in this study.   
 [List tests and procedures as appropriate.  Use bulleted format. Omit this section if no 
tests or procedures are being done more often than usual.] 
 
You will need these tests and procedures that are either being tested in this study or being 
done to see how the study is affecting your body. 
 [List tests and procedures as appropriate.  Use bulleted format.  Omit this section if no 
tests or procedures are being tested in this study or required for safety monitoring.] 
 
[For dose-finding studies:] You will be treated with a dose of the drugs that your doctor 
thinks is safe for you.  Not all patients will get the same doses of the drugs.  At the 
beginning of the study, a few patients will be treated with low doses of the drugs.  If these 
doses do not cause bad side effects, the doses will slowly be made higher for new patients 
who take part in the study.   
 
[For randomized studies:]    You will be "randomized" into one of the study groups 
described below.  Randomization means that you are put into a group by chance.  A 
computer program will place you in one of the study groups.  Neither you nor your doctor 
can choose the group you will be in.  You will have an [equal/one in three/etc.] chance of 
being placed in any group. 
 
If you are in group 1 (often called "Arm A") … [Explain what will happen for this group 
with clear indication of which interventions depart from routine care.]  
 
If you are in group 2 (often called "Arm B")… [Explain what will happen for this group 
with clear indication of which interventions depart from routine care.]  
 
[For studies with more than two groups, an explanatory paragraph containing the same type 
of information should be included for each group.] 
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When I am finished taking [drugs or intervention]…[Explain the follow-up tests, 
procedures, exams, etc. required, including the timing of each and whether they are part of 
standard cancer care or part of standard care but being performed more often than usual or 
being tested in this study.  Define the length of follow-up.]  
 
[Optional Feature:  In addition to the mandatory narrative explanation found in the preceding 
text, a simplified calendar (study chart) or schema (study plan) may be inserted here. The 
schema from the protocol should not be used as it is too complex, however a simplified version of 
the schema is encouraged.  Instructions for reading the calendar or schema should be included. 
See examples.] 
 
Study Chart [Example] 
 
You will receive [drug(s) or intervention] every [insert appropriate number of days or weeks] 
in this study.  This [insert appropriate number of days or weeks] period of time is called a 
cycle.  The cycle will be repeated [insert appropriate number] times.  Each cycle is numbered 
in order.  The chart below shows what will happen to you during Cycle 1 and future 
treatment cycles as explained previously.  The left-hand column shows the day in the cycle 
and the right-hand column tells you what to do on that day. 
 
Cycle 1 
Day What you do 
Two days before 
starting study 
 Get routine blood tests. 
Day before starting 
study 
 Check-in to _____________ the evening before starting study. 
Day 1 
 Begin taking ______ once a day. Keep taking _____ until the end of study, unless 
told to stop by your health care team. 
Day 2  Leave _______________ and go to where you are staying. 
Day 8  Get routine blood tests. 
Day 15  Get routine blood tests. 
Day 22  Get routine blood tests.  
Day 28 
 Get routine blood tests and exams. 
 Get 2nd chest x-ray for research purposes. 
Day 29 
 Return to your doctor‟s office at _______ [insert appointment time] for your next 
exam and to begin the next cycle. 
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Future cycles 
Day What you do 
Days 1-28 
 Keep taking _____ once a day if you have no bad side effects and cancer is not 
getting worse.  Call the doctor at _____________ [insert phone number] if you do 
not know what to do. 
 Get routine blood tests each week (more if your doctor tells you to). 
 Get routine blood tests and exams every cycle (more if your doctor tells you to). 
 Get routine X-rays, CT scans, or MRIs every other cycle (more if your doctor tells 
you to). 
Day 29 
 Return to your doctor‟s office at _______ [insert appointment time] for your next 
exam and to begin the next cycle. 
 
 
Study Plan [Example] 
 
Another way to find out what will happen to you during the study is to read the chart 
below.  Start reading at the top and read down the list, following the lines and arrows.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Breast Cancer Surgery 
Medicines used in this study 
 
Doxorubicin + Cyclophophamide by vein – given once every 21 days and repeated 4 times 
Randomize 
 
(You will be in one Group or the other) 
Group 2 
 
No Paclitaxel 
Group 1 
Paclitaxel by vein 
 
Every 21 days for 4 visits 
Start Here 
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How long will I be in the study? 
 
You will be asked to take [drugs or intervention] for  (months, weeks/until a certain event).  
After you are finished taking [drugs or intervention], the study doctor will ask you to visit 
the office for follow-up exams for at least [indicate time frames and requirements of follow-up. 
When appropriate, state that the study will involve long-term follow-up and specify time frames 
and requirements of long-term follow-up. For example, “We would like to keep track of your 
medical condition for the rest of your life.  We would like to do this by calling you on the 
telephone once a year to see how you are doing.  Keeping in touch with you and checking on 
your condition every year helps us look at the long-term effects of the study.”] 
 
 
Can I stop being in the study? 
 
Yes.  You can decide to stop at any time.  Tell the study doctor if you are thinking about 
stopping or decide to stop.  He or she will tell you how to stop safely.  
 
It is important to tell the study doctor if you are thinking about stopping so any risks from 
the [drugs or intervention] can be evaluated by your doctor.  Another reason to tell your 
doctor that you are thinking about stopping is to discuss what follow up care and testing 
could be most helpful for you. 
 
The study doctor may stop you from taking part in this study at any time if he/she believes it is in 
your best interest; if you do not follow the study rules; or if the study is stopped. 
 
 
What side effects or risks can I expect from being in the study?  
 
You may have side effects while on the study.  Everyone taking part in the study will be 
watched carefully for any side effects.  However, doctors don‟t know all the side effects that 
may happen.  Side effects may be mild or very serious. Your health care team may give you 
medicines to help lessen side effects. Many side effects go away soon after you stop taking 
the [drug(s) or intervention].  In some cases, side effects can be serious, long lasting, or may 
never go away. [The next sentence should be included if appropriate. There also is a risk of 
death.]   
 
You should talk to your study doctor about any side effects that you have while taking part in the 
study.    
 
Risks and side effects related to the [procedures, drugs, interventions, and devices] include 
those which are: 
 
Likely 
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 Less Likely   
   
   
  
   
Rare but serious 
   
   
  
   
[Notes for consent form authors regarding the presentation of risks and side effects: 
 Using a bulleted format, list risks and side effects related to the investigational aspects of 
the trial.  Side effects of supportive medications should not be listed unless they are 
mandated by the study.  
 The possibility that unanticipated (or currently unknown) or exacerbated adverse events 
could occur with the combined study agents because they form a new or untested 
combination should be noted. 
 If available, CAEPR (Comprehensive Adverse Events and Potential Risks) document(s) 
should be used to determine the risks and side effects that should be included in the 
consent.  These side effects should be presented in layman‟s terms.  Consent form authors 
should contact AdEERSMD@tech-res.com to obtain CAEPRs (if available) for the study 
agent(s). 
 List by regimen the physical and nonphysical risks and side effects of participating in the 
study in three categories:  1." likely"; 2. "less likely”; 3. “rare but serious".  
 There is no standard definition of "likely" and "less likely”.  As a guideline, “likely” can 
be viewed as occurring in greater than 20% of patients and “less likely” in less than or 
equal to 20% of patients.  However, this categorization should be adapted to specific 
study agents by the principal investigator. 
 In the “likely” and “less likely” categories, identify those side effects that may be 
„serious‟.  „Serious‟ is defined as side effects that may require hospitalization or may be 
irreversible, long-term, life threatening or fatal.   
 Side effects that occur in less than 2-3% of patients do not have to be listed unless they 
are serious, and should then appear in the “rare but serious” category.  
 Physical and nonphysical risks and side effects should include such things as the inability 
to work.  Whenever possible, describe side effects by how they make a patient feel, for 
example, “Loss of red blood cells, also called anemia, can cause tiredness, weakness and 
shortness of breath.” 
 For some investigational drugs/interventions/devices, there may be side effects that have 
been noted during treatment; however, not enough data are available to determine if the 
side effect is related to the drug/intervention/device.  Because some local IRBs request to 
be informed of these possible side effects, this information, when available, is provided to 
the study chair.  Inclusion of this information in the informed consent document is not 
mandatory.  However, if included, these side effects should be listed under a separate 
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category titled “Side effects reported by patients, but not proven to be caused by 
(drug/intervention/device)”.  Side effects in this category do not have to be labeled as 
“likely”, “less likely” or “rare but serious” and should not be repeated here if they 
appear in a previous category.  Similar to the other categories, these side effects should 
be listed in a bulleted format.]   
 
Reproductive risks:  You should not become pregnant or father a baby while on this study 
because the drugs in this study can affect an unborn baby.  Women should not breastfeed a 
baby while on this study.  It is important you understand that you need to use birth control 
while on this study.  Check with your study doctor about what kind of birth control 
methods to use and how long to use them.  Some methods might not be approved for use in 
this study. [Include a statement about possible sterility when appropriate.  For example, “Some 
of the drugs used in the study may make you unable to have children in the future.”  If 
appropriate include a statement that pregnancy testing may be required.] 
 
For more information about risks and side effects, ask your study doctor. 
 
 
Are there benefits to taking part in the study? 
 
Taking part in this study may or may not make your health better.  While doctors hope 
[procedures, drugs, interventions, devices] will be more useful against cancer compared to 
the usual treatment, there is no proof of this yet.  We do know that the information from 
this study will help doctors learn more about [procedures, drugs, interventions, devices] as a 
treatment for cancer.  This information could help future cancer patients. 
 
 
What other choices do I have if I do not take part in this study? 
 
Your other choices may include: 
 Getting treatment or care for your cancer without being in a study 
 Taking part in another study 
 Getting no treatment 
 
[Additional bullets should include, when appropriate, alternative specific procedures or 
treatments.] 
 
 [For studies involving end-stage cancer, add the following paragraph as an additional 
bullet.] Getting comfort care, also called palliative care.  This type of care helps 
reduce pain, tiredness, appetite problems and other problems caused by the cancer.  
It does not treat the cancer directly, but instead tries to improve how you feel.  
Comfort care tries to keep you as active and comfortable as possible.   
 
Talk to your doctor about your choices before you decide if you will take part in this study. 
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Will my medical information be kept private?  
 
We will do our best to make sure that the personal information in your medical record will be 
kept private.  However, we cannot guarantee total privacy.  Your personal information may be 
given out if required by law.  If information from this study is published or presented at scientific 
meetings, your name and other personal information will not be used.  
 
Organizations that may look at and/or copy your medical records for research, quality 
assurance, and data analysis include: 
 [List relevant organizations like study sponsor(s), local IRB, etc.]  
 The National Cancer Institute (NCI) and other government agencies, like the Food 
and Drug Administration (FDA), involved in keeping research safe for people 
 Pharmaceutical Collaborator [This generic language is consistent with the “Standard 
Protocol Language”, and allows for any potential changes in company designations.  
Please do not specify the name of the company.] 
 
[Note to Local Investigators: The NCI has recommended that HIPAA regulations be addressed 
by the local institution.  The regulations may or may not be included in the informed consent 
form depending on local institutional policy.] 
 
 
What are the costs of taking part in this study? 
 
You and/or your health plan/ insurance company will need to pay for some or all of the costs of 
treating your cancer in this study.  Some health plans will not pay these costs for people taking 
part in studies.  Check with your health plan or insurance company to find out what they will pay 
for.  Taking part in this study may or may not cost your insurance company more than the cost of 
getting regular cancer treatment.  
 
(If applicable, inform the patient of any tests or procedures for which there is no charge. 
Indicate if the patient and/or health plan is likely to be billed for any charges associated with 
these „free‟ tests or procedures.)  
   
(Include the following section if a study agent is manufactured by a drug company and provided 
at no charge) 
 
The (identify study agent supplier here using the most appropriate choice of the following 
options: NCI, Cooperative Group, or another NCI-supported Clinical Trials Network) will 
supply the [study agent(s)] at no charge while you take part in this study.  The (insert name 
of study agent supplier identified in first sentence) does not cover the cost of getting the [study 
agent(s)] ready and giving it to you, so you or your insurance company may have to pay for 
this.  
 
Even though it probably won‟t happen, it is possible that the manufacturer may 
not 
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continue to provide the [study agent(s)] to the (insert name of study agent supplier identified in 
first sentence) for some reason.  If this would occur, other possible options are: 
 
 You might be able to get the [study agent(s)] from the manufacturer or your 
pharmacy but you or your insurance company may have to pay for it. 
 
 If there is no [study agent(s)] available at all, no one will be able to get more and the 
study would close. 
 
If a problem with getting [study agent(s)] occurs, your study doctor will talk to you about 
these options. (End of section) 
 
(Include the following section if a study agent is manufactured by the NCI and provided at no 
charge) 
 
The NCI will provide the [study agent(s)] at no charge while you take part in this study.  
The NCI does not cover the cost of getting the [study agent(s)] ready and giving it to you, so 
you or your insurance company may have to pay for this. 
 
Even though it probably won‟t happen, it is possible that the NCI may not be able to 
continue to provide the [study agent(s)] for some reason.  If this would happen, the study 
may have to close.  Your study doctor will talk with you about this, if it happens.  (End of 
section)  
 
You will not be paid for taking part in this study. 
 
For more information on clinical trials and insurance coverage, you can visit the National 
Cancer Institute‟s Web site at http://cancer.gov/clinicaltrials/understanding/insurance-coverage. 
You can print a copy of the “Clinical Trials and Insurance Coverage” information from this 
Web site. 
 
Another way to get the information is to call 1-800-4-CANCER (1-800-422-6237) and ask them 
to send you a free copy. 
 
 
What happens if I am injured because I took part in this study? 
 
It is important that you tell your study doctor, __________________ [investigator‟s 
name(s)], if you feel that you have been injured because of taking part in this study.  You 
can tell the doctor in person or call him/her at __________________ [telephone number]. 
 
You will get medical treatment if you are injured as a result of taking part in this study.  
You and/or your health plan will be charged for this treatment.   The study will not pay for 
medical treatment.   
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What are my rights if I take part in this study? 
 
Taking part in this study is your choice.  You may choose either to take part or not to take 
part in the study.  If you decide to take part in this study, you may leave the study at any 
time.   No matter what decision you make, there will be no penalty to you and you will not 
lose any of your regular benefits.  Leaving the study will not affect your medical care.  You 
can still get your medical care from our institution.    
 
We will tell you about new information or changes in the study that may affect your health 
or your willingness to continue in the study. 
 
In the case of injury resulting from this study, you do not lose any of your legal rights to 
seek payment by signing this form.   
 
 
Who can answer my questions about the study? 
 
You can talk to your study doctor about any questions or concerns you have about this 
study.  Contact your study doctor __________________ [name(s)] at __________________ 
[telephone number]. 
 
For questions about your rights while taking part in this study, call the 
________________________ [name of center] Institutional Review Board (a group of people 
who review the research to protect your rights) at __________________ [telephone 
number].  [Note to Local Investigator: Contact information for patient representatives or other 
individuals in a local institution who are not on the IRB or research team but take calls regarding 
clinical trial questions can be listed here.]    
 
*You may also call the Operations Office of the NCI Central Institutional Review Board 
(CIRB) at 888-657-3711 (from the continental US only).   [*Only applies to sites using the 
CIRB.] 
 
Please note:  This section of the informed consent form is about additional research studies 
that are being done with people who are taking part in the main study.   You may take part 
in these additional studies if you want to.  You can still be a part of the main study even if 
you say „no‟ to taking part in any of these additional studies. 
 
You can say “yes” or “no” to each of the following studies.  Please mark your choice for 
each study.   
 
[Insert information about companion studies here.  Provide yes/no options at each decision 
point.  The following studies are included as examples therefore are written with italicized font.  
Any text provided for patients should use the same non-italicized font as used for the rest of the 
informed consent document.]   
 
[Example: Quality of Life study] 
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Quality of Life Study 
 
We want to know your view of how your life has been affected by cancer and its treatment. This 
“Quality of life” study looks at how you are feeling physically and emotionally during your 
cancer treatment. It also looks at how you are able to carry out your day-to-day activities. 
 
This information will help doctors better understand how patients feel during treatments and 
what effects the medicines are having.  In the future, this information may help patients and 
doctors as they decide which medicines to use to treat cancer. 
 
You will be asked to complete 3 questionnaires: one on your first visit, one 6 months later, and 
the last one 12 months after your first visit.  It takes about 15 minutes to fill out each 
questionnaire.   
 
If any questions make you feel uncomfortable, you may skip those questions and not give an 
answer. 
 
If you decide to take part in this study, the only thing you will be asked to do is fill out the three 
questionnaires.  You may change your mind about completing the questionnaires at any time. 
 
Just like in the main study, we will do our best to make sure that your personal information will 
be kept private. 
 
Please circle your answer. 
 
I choose to take part in the Quality of Life Study.  I agree to fill out the three Quality of Life 
Questionnaires. 
 
YES     NO 
 
 
[Example: Use of Tissue for Research] 
 
[The following example of tissue consent has been taken from the NCI Cancer Diagnosis 
Program‟s model tissue consent form found at the following url        
http://www.cancerdiagnosis.nci.nih.gov/specimens/model.pdf ] 
 
Consent Form for Use of Tissue for Research 
 
About Using Tissue for Research  
 
You are going to have a biopsy (or surgery) to see if you have cancer.  Your doctor will remove 
some body tissue to do some tests.  The results of these tests will be given to you by your doctor 
and will be used to plan your care.  
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We would like to keep some of the tissue that is left over for future research.  If you agree, this 
tissue will be kept and may be used in research to learn more about cancer and other diseases. 
Please read the information sheet called "How is Tissue Used for Research" to learn more about 
tissue research.  
 
Your tissue may be helpful for research whether you do or do not have cancer.  The research 
that may be done with your tissue is not designed specifically to help you.  It might help people 
who have cancer and other diseases in the future.  
 
Reports about research done with your tissue will not be given to you or your doctor.  These 
reports will not be put in your health record.  The research will not have an effect on your care.  
 
Things to Think About  
 
The choice to let us keep the left over tissue for future research is up to you.  No matter what you 
decide to do, it will not affect your care.  
 
If you decide now that your tissue can be kept for research, you can change your mind at any 
time.  Just contact us and let us know that you do not want us to use your tissue.  Then any tissue 
that remains will no longer be used for research.  
 
In the future, people who do research may need to know more about your health.  While the xyz 
may give them reports about your health, it will not give them your name, address, phone 
number, or any other information that will let the researchers know who you are.  
 
Sometimes tissue is used for genetic research (about diseases that are passed on in families). 
Even if your tissue is used for this kind of research, the results will not be put in your health 
records.  
 
Your tissue will be used only for research and will not be sold.  The research done with your 
tissue may help to develop new products in the future.  
 
Benefits   
 
The benefits of research using tissue include learning more about what causes cancer and other 
diseases, how to prevent them, and how to treat them.  
 
Risks  
 
The greatest risk to you is the release of information from your health records.   We will do our 
best to make sure that your personal information will be kept private.  The chance that this 
information will be given to someone else is very small.  
 
Making Your Choice  
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Please read each sentence below and think about your choice.  After reading each sentence, 
circle "Yes" or "No".  If you have any questions, please talk to your doctor or nurse, or call our 
research review board at IRB's phone number.  
 
No matter what you decide to do, it will not affect your care. 
 
1. My tissue may be kept for use in research to learn about, prevent, or treat cancer.  
 
Yes No 
 
2. My tissue may be kept for use in research to learn about, prevent or treat other health 
problems (for example: diabetes, Alzheimer's disease, or heart disease).  
 
Yes No 
 
3. Someone may contact me in the future to ask me to take part in more research.  
 
Yes No 
 
 
Where can I get more information? 
 
You may call the National Cancer Institute's Cancer Information Service at:  
 
1-800-4-CANCER (1-800-422-6237) or TTY: 1-800-332-8615 
 
You may also visit the NCI Web site at http://cancer.gov/ 
 
 For NCI‟s clinical trials information, go to: http://cancer.gov/clinicaltrials/ 
 
 For NCI‟s general information about cancer, go to http://cancer.gov/cancerinfo/ 
 
You will get a copy of this form.    If you want more information about this study, ask your 
study doctor. 
 
Signature 
 
I have been given a copy of all _____ [insert total of number of pages] pages of this form.  I 
have read it or it has been read to me.  I understand the information and have had my 
questions answered.  I agree to take part in this study. 
 
Participant ____________________________________ 
 
Date _____________________________________ 
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APPENDIX A 
 
 
Performance Status Criteria 
 
ECOG Performance Status Scale Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 
Normal activity.  Fully active, able 
to carry on all pre-disease 
performance without restriction. 
100 
Normal, no complaints, no evidence 
of disease. 
90 
Able to carry on normal activity; 
minor signs or symptoms of disease. 
1 
Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work). 
80 
Normal activity with effort; some 
signs or symptoms of disease. 
70 
Cares for self, unable to carry on 
normal activity or to do active work. 
2 
In bed <50% of the time.  
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours. 
60 
Requires occasional assistance, but 
is able to care for most of his/her 
needs. 
50 
Requires considerable assistance and 
frequent medical care. 
3 
In bed >50% of the time.  Capable 
of only limited self-care, confined 
to bed or chair more than 50% of 
waking hours. 
40 
Disabled, requires special care and 
assistance. 
30 
Severely disabled, hospitalization 
indicated.  Death not imminent. 
4 
100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair. 
20 
Very sick, hospitalization indicated. 
Death not imminent. 
10 
Moribund, fatal processes 
progressing rapidly. 
5 Dead. 0 Dead. 
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APPENDIX B 
 
 
CTEP MULTICENTER GUIDELINES 
 
 
If an institution wishes to collaborate with other participating institutions in performing a CTEP 
sponsored research protocol, then the following guidelines must be followed. 
 
Responsibility of the Protocol Chair  
 The Protocol Chair will be the single liaison with the CTEP Protocol and Information 
Office (PIO).  The Protocol Chair is responsible for the coordination, development, 
submission, and approval of the protocol as well as its subsequent amendments.  The 
protocol must not be rewritten or modified by anyone other than the Protocol Chair.  
There will be only one version of the protocol, and each participating institution will use 
that document.  The Protocol Chair is responsible for assuring that all participating 
institutions are using the correct version of the protocol. 
 The Protocol Chair is responsible for the overall conduct of the study at all participating 
institutions and for monitoring its progress.  All reporting requirements to CTEP are the 
responsibility of the Protocol Chair.  
 The Protocol Chair is responsible for the timely review of Adverse Events (AE) to assure 
safety of the patients. 
 The Protocol Chair will be responsible for the review of and timely submission of data 
for study analysis. 
 
Responsibilities of the Coordinating Center 
 Each participating institution will have an appropriate assurance on file with the Office 
for Human Research Protection (OHRP), NIH.  The Coordinating Center is responsible 
for assuring that each participating institution has an OHRP assurance and must maintain 
copies of IRB approvals from each participating site.  
 Prior to the activation of the protocol at each participating institution, an OHRP form 310 
(documentation of IRB approval) must be submitted to the CTEP PIO. 
 The Coordinating Center is responsible for central patient registration.  The Coordinating 
Center is responsible for assuring that IRB approval has been obtained at each 
participating site prior to the first patient registration from that site. 
 The Coordinating Center is responsible for the preparation of all submitted data for 
review by the Protocol Chair. 
 The Coordinating Center will maintain documentation of AE reports.  There are two 
options for AE reporting: (1) participating institutions may report directly to CTEP with a 
copy to the Coordinating Center, or (2) participating institutions report to the 
Coordinating Center who in turn report to CTEP.  The Coordinating Center will submit 
AE reports to the Protocol Chair for timely review. 
 Audits may be accomplished in one of two ways:  (1) source documents and research 
records for selected patients are brought from participating sites to the Coordinating 
Center for audit, or (2) selected patient records may be audited on-site at participating 
sites.  If the NCI chooses to have an audit at the Coordinating Center, then the 
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Coordinating Center is responsible for having all source documents, research records, all 
IRB approval documents, NCI Drug Accountability Record forms, patient registration 
lists, response assessments scans, x-rays, etc. available for the audit. 
 
Inclusion of Multicenter Guidelines in the Protocol 
 The protocol must include the following minimum information:  
 The title page must include the name and address of each participating institution and 
the name, telephone number and e-mail address of the responsible investigator at each 
participating institution. 
 The Coordinating Center must be designated on the title page. 
 Central registration of patients is required.  The procedures for registration must be 
stated in the protocol. 
 Data collection forms should be of a common format.  Sample forms should be 
submitted with the protocol.  The frequency and timing of data submission forms to 
the Coordinating Center should be stated. 
 Describe how AEs will be reported from the participating institutions, either directly 
to CTEP or through the Coordinating Center. 
 Describe how Safety Reports and Action Letters from CTEP will be distributed to 
participating institutions. 
 
Agent Ordering 
 Except in very unusual circumstances, each participating institution will order DCTD-
supplied investigational agents directly from CTEP.  Investigational agents may be 
ordered by a participating site only after the initial IRB approval for the site has been 
forwarded by the Coordinating Center to the CTEP PIO.  
 
 
 
 
 
